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Abstract
HIV-1 attacks vital cells in the human immune system. HIV-1 differs from many
viruses since it is characterized by a very high genetic variability. This means that
many variants of HIV-1 virus can be generated in a single infected patient in the
course of one day. HIV-1 hypervariability causes drug resistance and, consequently,
medical treatment failure. Targeting the interactions between proteins from HIV-1
and from Homo sapiens may represent an excellent solution for drug design because
it may avoid drug resistance problems. However rational drug design requires the
knowledge of the structural determinants of the complexes, in most cases experi-
mentally unavailable.
In this thesis I have used a variety of computational approaches for the structural
prediction of specific HIV-1 protein / cellular partners complexes.
The first model I predicted is HIV-1 integrase (IN) in complex with one of its
essential cellular partners, human prolyl-isomerase-1 (hPin1). This interaction
occurs during viral integration, a crucial step of HIV-1 life cycle since it generates
the DNA-template for productive infection. The model has been validated against
experiments performed by the Molecular Medicine group of Prof. Mauro Giacca,
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy. The
model provides a rationale for the effect of mutating charged residues at the HIV-1
IN surface, which are known to hamper virus replication in vivo without affecting
integrase enzymatic activity.
Next, I predicted the structural determinants of HIV-1 trans-activator of tran-
scription (Tat) in complex with human p300/(CREB-binding protein) -
associated factor (PCAF) bromodomain, which occurs during viral transcrip-
tion step. PCAF binds to Tat only when the latter is acetylated at lysine 50.
The proposed complex is consistent with the available experimental data reported.
Acetylation is one of the most common protein post-translational modifications.
Hence, our model may help in defining the structural determinants of other protein
interactions involving lysine acetylation.
The work presented in my thesis might help developing new ligands capable of
interfering with HIV-1 interactions.
Zusammenfassung
Wechselwirkungen von HIV-1-Proteinen mit ihren zellula¨ren Partnern:
Erkenntnisse aus computergestu¨tzten Rechenverfahren
HIV-1 greift lebende Zellen des menschlichen Immunsystems an. HIV-1 unterschei-
det sich von vielen Viren durch eine sehr hohe genetische Variabilita¨t. Dies be-
deutet, dass viele Varianten des HIV-1-Virus in einem einzigen infizierten Patienten
im Laufe eines Tages erzeugt werden ko¨nnen. HIV-1 Hypervariabilita¨t verursacht
Arzneimittelresistenz und folglich ein Versagen der medizinischen Behandlung. Die
Untersuchung der Wechselwirkungen zwischen Proteinen von HIV-1 und Homo sapi-
ens kann eine hervorragende Lo¨sung fu¨r Wirkstoffdesign sein, weil sie Probleme
mit Resistenzen vermeiden kann. Allerdings erfordert rationales Wirkstoffdesign die
Kenntnis der strukturellen Bestimmungsfaktoren der Komplexe, welche in den meis-
ten Fa¨llen nicht experimentell verfu¨gbar sind.
In dieser Arbeit habe ich eine Vielzahl von computergestu¨tzten Ansa¨tzen fu¨r die
strukturelle Vorhersage von Komplexen spezifischer HIV-1 Proteine mit zellula¨ren
Partnern eingesetzt. Das erste Modell, das ich vorhergesagt habe, ist HIV-1-
Integrase (IN) im Komplex mit einem seiner wesentlichen zellula¨ren Partner, die
menschliche Prolyl-Isomerase-1 (hPin1). Diese Wechselwirkung tritt wa¨hrend
der viralen Integration auf, ein entscheidender Schritt des HIV-1 Lebenszyklus, da
es die DNA-Vorlage fu¨r ergiebige Infektionen erzeugt. Das Modell hat sich durch
Experimente, die von der Molecular Medicine Gruppe von Prof. Mauro Giacca,
International Centre for Genetic Engineering and Biotechnology, Trieste, Italien,
durchgefu¨hrt wurden, besta¨tigt. Das Modell liefert eine Erkla¨rung fu¨r die Wirkung
der Mutation geladener Reste an der HIV-1 IN Oberfla¨che, die bekanntlich die Virus-
replikation in vivo hemmen, ohne die enzymatische Aktivita¨t der Integrase zu beein-
tra¨chtigen.
Anschliessend habe ich die strukturellen Bestimmungsfaktoren von HIV-1-trans-
Aktivator der Transkription (Tat) im Komplex mit der menschlichen p300/(CREB-
Bindeprotein)-assoziierter Faktor (PCAF) Bromodoma¨ne, welcher wa¨hrend
der viralen Transkription auftritt, vorhergesagt. PCAF bindet Tat nur dann, wenn
letzteres an der Lysin 50 Aminosa¨ure acetyliert ist. Der vorgeschlagene Komplex
steht in Einklang mit den verfu¨gbaren experimentellen Literaturdaten. Acetylierung
ist eine der ha¨ufigsten posttranslationalen Modifikationen von Proteinen. Daher
kann unser Modell bei der Ermittlung der strukturellen Bestimmungsfaktoren von
anderen Protein-Wechselwirkungen, die mit Lysin Acetylierung verbunden sind,
helfen.
Die in meiner Doktorarbeit vorgestellten Studien ko¨nnten helfen, neue Liganden zu
entwickeln, die in der Lage sind, in die HIV-1 Wechselwirkungen einzugreifen.
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1
Introduction
The human immunodeficiency virus (HIV) continues to be a major threat for human
mankind. More than 34 million people are currently infected by HIV [1, 2, 3]. Only
in 2011, approximately 1.7 million people died from acquired immunodeficiency syn-
drome (AIDS)-related causes [1, 2, 3]. (Figure 1.1 ). AIDS is the 1st cause of death
in undeveloped countries [2].
Figure 1.1 A global view of HIV infection (33.5 million people living with HIV
in 2010), the color illustrates the rate of adult infections (age 15-49).
1: Map adapted from UNAIDS 2010 Report on the global AIDS epidemic. Available
from www.unaids.org/globalreport. Data used by kind permission of Joint United
Nations Programme on IV/AIDS (UNAIDS).
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Current anti-AIDS drugs target viral proteins 1. They delay the progression of the
disease and therefore prolong patient’s survivals [4, 5, 6]. Unfortunately, however,
frequent HIV-1 mutations alter the shape of the targeted viral proteins, hence reduc-
ing the efficacy of the drugs [7, 8, 9]. This drug resistance is an ultrafast Darwinian
process, which may arise from functional variants which are less affected by current
drugs than the wild-type proteins [4].
Targeting HIV-1 protein/human protein interactions is an excellent strategy to over-
come some of the problems associated with drug resistance, as the human proteins
cannot mutate [4, 5, 10, 11, 12]. The paucity of experimental structural information
on such complexes however severely hampers the rational design of ligands to these
complexes 2. Computational approaches are then the method of choice to inves-
tigate protein/protein complexes. In particular, docking procedures, when driven
and aided by experiments, are showing increasingly accurate results [13, 14, 15, 16].
Improvements in the algorithms, including flexible docking, which allows for con-
formation changing of proteins upon binding [13, 16, 17, 18, 19, 20], have largely
increased the domain of applicability of this methodology.
If the structures of the two interacting proteins have not been determined exper-
imentally, e.g. via X-ray crystallography or NMR spectroscopy [13, 21], then ho-
mology modeling can be often used to make structural predictions provided that
proteins encoded by orhtologous genes have been already structurally characterized
[22, 22, 23, 24, 25]. This modeling process can greatly benefit from the input pro-
vided by sequence analysis (e.g. the conservation of specific residues inferred from
multiple sequence alignments) and by experimental knowledge (e.g. mutagenesis,
mass spectrometry, and NMR techniques including chemical shift perturbations,
residual dipolar couplings, and hydrogen/deuterium exchange) [16, 17, 26, 27].
Here I used these computational approaches in the context of two key steps of HIV-
1 replication. The work has been carried out in collaboration with the Molecular
Medicine group of Mauro Giacca, International Centre for Genetic Engineering and
Biotechnology (ICGEB), Trieste, Italy. 3
First, I have focused on viral integration. This process follows the completion of
reserve transcription in the cytoplasm of the infected cell and later ends with the
initiation of the transcription from the proviral DNA [28, 29, 30]. In the context
of HIV-1 integration, viral DNA is required to do the strand transfer. The enzyme
HIV-1 integrase (IN) carries out the initial DNA breaking and joining reac-
tions responsible for the attachment of HIV-1 cDNA to the host DNA [28, 29, 30].
A recent investigation by the group of Prof. Giacca has shown that the human
1 These are the viral entry and the HIV-1 encoded enzymes, including protease, reverse tran-
scriptase, and integrase.
2 Currently there are 1,153 structures of single HIV-1 proteins in the PDB
(http://www.pdb.org/) to be compared to approximately 88 HIV-1 protein/human complex
structures.
3 Some of the calculations presented here were carried out by Dr. Vincenzo Carnevale (Temple
University, US) and by Dr. Vanessa Leone (Max Planck Institute of Biophysics, Germany).
3prolyl-isomerase-1 (hPin1) protein is a requisite for efficient HIV-1 integration
and infection [31]. Targeting hPin1/HIV-1 IN interactions may be therefore a valu-
able strategy for antiviral intervention. hPin1 consists of two domains, namely WW
and PPIase [32, 33]. Here I have predicted the structure of this complex based on
available experimental results from Prof. Giacca’s lab. The accuracy of my model
has been established by site-directed mutagenesis experiments by Prof. Giacca.
These experiments involve residues predicted to play a key role for the binding. My
modeling suggests that: (i) hPin1-PPIase domain induces a significant structural
modification of HIV-1 IN upon the binding without affecting the structure of the
catalytic core of HIV-1 IN. (ii)Protein/protein interactions involve residues under-
going mutations that impair HIV-1 replication in vivo without significantly affecting
HIV-1 IN’s enzymatic activity (so called ’Class II mutations’) [34, 35, 36, 37]. We
suggest that this intriguing feature is due, at least in part, to the fact that mutations
of these residues affect HIV-1 IN•hPin1 interactions, and hence IN stability in vivo.
The second step studied here is the binding of the HIV-1 trans-activator of tran-
scription (Tat) protein to human p300/(CREB-binding protein)-associated
factor (PCAF) during the viral transcription. Transcription is an essential event in
the replication cycle of HIV-1. It involves a complex interplay of viral and multiple
cellular proteins [38, 39]. In HIV-1 transcription context, Tat plays a pivotal role
because it stimulates transcription by binding to the trans-activator response (TAR)
element [40, 41, 42, 43]. Tat has also an ability to bind multiple partners and adapts
its conformations according to the cellular partners [44, 45]. Tat transactivation
activity is dependent on lysine acetylation and its association with nuclear histone
acetyltransferases p300/CBP (CREB binding protein) and PCAF [38, 39, 40, 45, 46].
Both Tat and PCAF bromodomain are promising targets for antiviral drugs discov-
ery [47, 48, 49].
Here, I predicted the structural determinants of the Tat and PCAF bromodomain
complex for the common HIV-1BRU variant which is the representative of the sub-
type B, commonly found in infected individuals in Europe and North America [50].
Our model is consistent with the available experimental data reported and adds
novel information to Tat•PCAF bromodomain interactions. The model may help
in defining the structural determinants of other protein interactions involving lysine
acetylation [46].
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2
HIV-1 Overview and Targets for
HIV-1 Drug Design
Introduction
Human Immunodeficiency Virus (HIV) 1 is a virus that attacks the human immune
system causing Acquired Immunodeficiency Syndrome (AIDS). This occurs when
HIV encounters CD4+ T-cells, important components of the human immune system,
impairing their functions.
The first case of AIDS was reported in the United Kingdom in 1981 [51]. Everyday,
over 6,000 people become infected with HIV and over 5,000 people die from AIDS
[52]. By the end of 2010, an estimated 34 million people worldwide were living
with HIV, of which ten percent were children. AIDS is the 1st cause of death in
undeveloped countries [2].
Up to now two types of HIV are found: HIV-1 and HIV-2. The predominant virus is
HIV-1, while HIV-2 type is concentrated in West Africa [53]. This thesis is focused
on HIV-1 only.
Here I first describe the HIV-1 morphology, structure, and genome organization
(Section 1). Then I turn my attention to the HIV-1 life cycle (Section 2). The
next two Sections focus on the viral steps involving the two viral proteins under
study here, HIV-1 integrase (IN) (Section 3) and HIV-1 transactivator of
transcription (Tat) (Section 4). These viral steps involve the interactions be-
tween HIV-1 IN and Tat with human biomolecules. Hence, Section 3 and Section
4 also detail the structure and the function of the specific interactors that have been
studied in this thesis. The last Section provides a summary of one of the major
problems in antiviral therapy, that of drug resistance (Section 5).
1 HIV is assigned to the genus Lentivirus, subfamily Orthoretrovirinae and family Retroviridae.
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2.1 HIV-1 Morphology and Structure
2.1.1 HIV-1 Morphology
HIV-1 lineages are divided in four main groups, M (for Major), O (for Outlier), N
(for New, or Non-M, Non-O) and P [54, 55, 56]. 2 The vast majority of strains
found worldwide belong to the M group, which is further subdivided in 9 clades or
subtypes (A, B, C, D, F, G, H, J and K) [54, 55, 56, 57]. In this thesis I focused on
the HIV-1 in the major group.
HIV-1, like other virions, consists of a viral envelope and a viral core [59].
The viral envelope is the outer coat of the virus, around 120 nm in diameter [59, 60].
It is composed of two lipid layers, sequestered from the membrane of a previously
attacked human cell [59, 60, 61, 62]. Embedded throughout the viral envelope are
72 copies (on average) of a protein known as Env [59, 60, 61, 62]. Env copies
protrude or spike through the surface of the virus particle and consist of a cap made
of glycoprotein 120 (gp120), and a stem consisting of glycoprotein 41 (gp41) that
anchor the structure in the viral envelope. Much of the research to develop a vaccine
to prevent HIV-1 infection has focused on these envelope proteins [4, 5]. Between the
viral core and the viral envelope is the matrix protein called p17, which ensure the
integrity of the virion particle [59].The viral core constituted by a nucleodid made
up of 2,000 copies of the viral protein, p24 and a rod- or truncated-cone- shaped
nucleocapsid [59].3
The capsid surrounds two single strands of HIV-1 RNA, 9,749 nucleotides long [63],
each of which has a complete copy of the virus’s genes [59, 63, 64]. HIV-1’s core
also includes the nucleocapsid proteins, p6 and p7 (which protect the RNA from
digestion by nucleases) and enzymes that are indispensable for the development of
the virion [59, 63, 64].
2.1.2 Structural and Genome Organization
The genetic structure of virus contains both highly conserved and highly variable
regions [65]. The drug resistance is an evolutionary process that is characterized by
the accumulation of mutations mostly in high variable region [1, 52, 66]. The pres-
ence of these genetic alterations in the virus population limits therapeutic options
and reduces the chance of successful treatment [1, 52, 66].
The HIV-1 genome has (Figure 2.1):
2O group seems to be endemic and largely confined to Cameroon and neighboring countries in
West Central Africa, where these viruses represent a small minority of HIV-1 strains [54, 55, 56]
The N group is represented by a limited number of isolates from Cameroonian persons [55, 56].
In 2009 a new strain closely relating to gorilla simian immunodeficiency virus was discovered in a
Cameroonian woman. It was designated HIV-1 group P [57]. These four groups, M, N, O, P, may
represent four separate introductions of simian immunodeficiency virus into humans [58].
3The first model of its structure was compiled in 2006 using cryo-electron microscopy (cryo-EM)
and suggested that three copies of gp120-gp41 heterodimers are thought to form a trimer as the
envelope spike [60].
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• three structural genes (gag, pol, and env) that contain information needed to
make structural proteins for new virus particles [64].
• two regulatory genes (tat, rev) and four accessory genes (nef, vif, vpr, and vpu)
that contain information needed to produce proteins that control the ability
of HIV-1 to infect a cell, produce new copies of virus, or cause disease [64].
The ends of each strand of HIV-1 RNA contain an RNA sequence called the long
terminal repeat (LTR). Regions in the LTR act as switches to control production
of new viruses and can be triggered by proteins from either HIV-1 or the host cell
[64, 67].
2.1.2.1 The structural proteins
The products of gag, pol, and env genes are essential components of the retroviral
particle.
• Gag proteins: The gag gene encodes the 55-kilodalton (kD) Gag precursor
protein namely p55 [68]. After budding, p55 is cleaved by the virally encoded
protease during the process of viral maturation into four smaller proteins des-
ignated MA (matrix [p17]), CA (capsid [p24]), NC (nucleocapsid [p9]), and p6
[68].
• Gag-Pol precursor: The viral protease (PR), IN, RNase H, and reverse tran-
scriptase (RT) are always expressed within the context of a Gag-Pol fusion
protein [69]. During viral maturation, the virally encoded protease cleaves
the Pol polypeptide away from Gag and further digests it to separate the PR
(p10), RT (p50), RNAse H (p15), and IN (p31) activities [69].
• Protease: The HIV-1 PR is an aspartyl protease [70] that acts as a dimer. PR
activity is required for cleavage of the Gag and Gag-Pol polyprotein precursors
during virion maturation as described previously [70, 71].
• Reverse Transcriptase: The pol gene encodes RT. During the process of reverse
transcription, the polymerase makes a double stranded DNA copy of the dimer
of single stranded genomic RNA present in the virion [59, 72].
• Integrase: The HIV-1 IN is responsible for the chromosomal integration of the
newly synthesized double- stranded viral DNA into the host genomic DNA
[28, 73].
• Envelop proteins (Env): A cellular protease cleaves 160 kD Env (gp160) to
generate gp41 and gp120. gp41 contains the transmembrane domain of Env,
while gp120 is located on the surface of the infected cell and of the virion
through non covalent interactions with gp41[59, 74]. Env exists as a multi-
mer, most likely a trimer. Interactions between HIV-1 and CD4 are mediated
through specific domains of gp120 [74].
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Figure 2.1 Diagram of the HIV-1 genome. Violet color is used for core struc-
tural proteins encoded by gag, green is used for viral enzymes encoded by pol, red
for envelope structural proteins encoded by env. Other colors are for different genes
and proteins. (A) Genomic organization of HIV-1’s genome: gag : coding for the
viral capsid proteins; pol : notably, coding for reverse transcriptase (gag and pol to-
gether can be expressed in one long strand called ”gag-pol”); env : coding for HIV-1’s
envelope-associated proteins; tat, rev, nef, vif, vpr, vpu: the regulatory genes. Tat
and Rev are encoded by two exons (B) the encoded proteins colored as the same as
the coding genes (C) the virion structure consisting of an outer protein shell called a
capsid, an inner RNA core, and the viral matrix proteins lying between the envelope
and core. For detailed explanations see text.
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2.1.2.2 The regulatory proteins, Tat and Rev
The regulatory proteins modulate transcriptional and posttranscriptional steps of
virus gene expression and are essential for virus propagation.
• Tat: Tat is essential for HIV-1 transcription and replication. Unlike other
transactivators, which only bind to DNA, HIV-1 Tat can bind HIV-1 proviral
DNA [75], host cell DNA [76], viral RNA and host cell proteins; and affect
transcription [38, 39].
• Rev: Rev is a 13-kD sequence-specific RNA binding protein [77]. Produced
from fully spliced mRNAs, Rev acts to induce the transition from the early to
the late phase of HIV-1 gene expression [78].
2.1.2.3 The accessory proteins, Vpu, Vpr, Vif, and Nef
The accessory proteins are not absolutely required for viral replication in all in vitro
systems, but represent critical virulence factors in vivo. Nef is expressed from a
multiply spliced mRNA and is therefore Rev independent. In contrast, Vpr, Vpu,
and Vif are the product of incompletely spliced mRNA, and thus are expressed only
during the late, Rev-dependent phase of infection from singly spliced mRNAs. Most
of the small accessory proteins of HIV-1 have multiple functions [79, 80, 81].
2.2 HIV-1 life cycle
The HIV-1 replication cycle includes the following steps: entry to the cell by binding
to CD4 receptors and release of the HIV-1 core into the host cell; replicate and
transcripte by reverse transcriptase viral RNA genome to cDNA, integrate to human
genome, and transcription of the integrated DNA provirus into mRNA using the
host’s ribosomes. New virions are created by assembly and budding through the
infected cell membrane and subsequent maturation due to the actions of protease
(Figure 2.2) [72, 78, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,
99, 59].
In this thesis I will focus on understanding and characterizing protein - protein
complex structures in HIV-1 transcription and integration, the two crucial steps in
HIV-1 life cycle. Hence I will describe in details these two steps.
2.3 Integrase, integration to the host chromosome
and its role
To efficiently direct production of progeny virions, a retrovirus must insert a DNA
to the host chromosome [100, 101, 102]. This process is operated by the intasome, a
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Figure 2.2 Major steps in HIV-1 life cycle. Each step of the viral life cycle
is depicted by a number. Step 1: the attachment of the HIV-1 gp120 envelope to
the CD4 receptor. With the help of co-receptors (CCR5 or CXCR4), fusion with
the cell membrane results in entry of the viral core into the cytoplasm [82, 85, 86,
87, 88, 90, 91, 92, 95]. Steps 2: one of the virion RNAs is reverse transcribed
into cDNA and then dsDNA, this step happens in the cytoplasm [59]. Step 3:
Following reverse transcription, the viral DNA genome is then integrated into a host
chromosome in nucleus. Some of the viral proteins (Tat, Nef, Rev) are transcripted
in the early transcription [78, 83, 89, 96, 97, 99]. Step 4: transcription to mRNAs
of the integrated retroviral genes is performed by the host cell RNA polymerase II
[72, 98]. The viral mRNAs are processed by splicing to different lengths [72, 98].
Step 5: These mRNAs are exported from the nucleus to the cytoplasm. The
virus matures by protease releasing individual HIV proteins [84, 93]. Step 6: Viral
particles are formed through assembly of proteins, enzymes and RNA [94]. Step 7:
Viral particles are then extruded as mature virions by budding from the cell surface
[94].
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nucleoprotein complex composed of an IN multimer 4 assembled on the viral DNA
ends [104, 29]. In the first step, IN proteins catalyze the removal of two bases
from the 30 end of each viral DNA strand, leaving recessed 3’ hydroxyl groups
[105, 106, 107, 108]. This terminal cleavage reaction is required for proper integration
[109, 110]. Later the HIV-1 IN catalyzes the covalent attachment of hydroxyl groups
at the viral DNA termini to protruding 5’ phosphoryl ends of the host cell DNA
[105, 106].
HIV-1 IN is a 32-kDa protein, composed of 288 amino acids produced from the
C-terminal portion of the Pol gene product, and is an attractive target for new
anti-HIV-1 drugs [28, 30]. The functional IN enzyme is generated by proteolytic
cleavage of the Gag-Pol precursor polypeptide, mediated by the viral PR enzyme,
as occurs for other viral enzymes and proteins [111, 112, 113, 73]. All retroviral IN
proteins contain three canonical domains, connected by flexible linkers: a N-terminal
HH-CC zinc-binding domain (a three-helical bundle stabilized by coordination of
a Zn(II) cation), a catalytic core domain (RNaseH fold) and a C-terminal DNA-
binding domain (SH3 fold) [114]. I will refer to them by using NTD, CCD and CTD
abbreviations respectively.
Many cellular proteins have been reported to interact with HIV-1 IN, and at least
some of them are functionally relevant to the integration process [115]. The most
studied cellular factor is LEDGF/p75, HIV-1 IN exists as a homotetramer in vivo
when associated with this protein [115]. IN perhaps forms as a homotetramer when
it is bound to the DNA in a related IN of a prototypic foamy virus (PFV) [116].
HIV-1 IN is present as a monomer, homodimer, and homotetramer in vitro [112,
117, 118, 29, 119, 120, 121, 104, 122]. Only partial structures of HIV-1 IN without
DNA have so far been determined [115]. The structures of the monomer, dimer, and
higher order multimers have not been characterized yet. In this thesis, the structure
of full length HIV-1 IN monomer (monIN) is predicted by homology modeling based
on the structures of domains NTD-CCD [123], CCD-CTD [124] and PFV intasome
structure of IN [103].
It has been demonstrated that phosphorylation of HIV-1 integrase (IN) by cellular c-
Jun N-terminal kinase (JNK) is required for efficient HIV-1 infection and integration
in primary human T lymphocytes [31]. Proteins that are phosphorylated on the
serine-proline motif such as HIV-1 IN are potential targets for the human prolyl-
isomerase-1 (hPin1).
hPin1 is a protein that catalyzes the cis-trans isomerization of phosphorylated ser-
ine/phosphorylated threonine - proline (pSer/pThr-Pro) motifs and then alters the
catalytic activity, stability, subcellular localization, and the rate and extent of de-
phosphorylation of phospho-protein targets [32, 33, 125, 126]. hPin1 is a two-domain
protein including a catalytic domain, namely peptidyl prolyl isomerase (PPIase)
and a WW domain. The so called WW because it has two invariant Trp residues
[127, 33]. Both of these domains bind the pSer/pThr-Pro motif. WW domain acts
as a recognition module for the pSer/pThr-Pro motif and PPIase catalyzes the cis-
trans isomerization of pSer/pThr-Pro amide bonds [128, 129, 130]. However, the
HIV-1 IN•hPin1 complex has not determined experimentally yet.
4As our best knowledge, there is no further detail for the form of IN in complex with DNA than
”tetramer”, PFV IN perhaps also forms as homotetramer in associate with DNA [29, 103]
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In this thesis, the interactions of HIV-1 IN and hPin1 are investigated based on
available experimental structural information of the two single moieties and validated
by site mutagenesis experiments. The detail on structure of IN and in complex with
the two domains of hPin1 will be discussed in Chapter 4. ”Structural Reorganization
of HIV-1 Integrase upon Binding to the Cellular Prolyl-Isomerase Pin1”.
2.4 Transcription and the role of Tat
The production of HIV-1 mRNA from the integrated provirus requires several steps
that involve both cellular and viral proteins (Figure 2.2). HIV-1 Tat (transactivator
of transcription), Rev, and Nef are the first proteins to be produced after cDNA
synthesis by reverse transcriptase in the HIV-1 life cycle in cytoplasm, then they go
to the nucleus [38, 39]. I will focus on HIV-1 Tat since it plays a critical role in the
viral transcription [38]. In my thesis I have studied the HIV-1 Tat and p300/(CREB-
binding protein) - associated factor (PCAF) interactions.
HIV-1 Tat is a 14-kDa protein encoded by two exons; 1-72 amino acid from exon
1 and 73-86 (or 73-101 depending on the virus strain) from exon 2 (Chapter 5,
Fig. 1) [38]. Post translational modifications in HIV-1 Tat such as acetylation
[40, 41, 42, 131, 132, 133, 134, 135], phosphorylation [136, 137], methylation [138,
139] and ubiquitination [140, 141] play an important role in HIV-1 Tat regulatory
mechanisms. Especially, HIV-1 Tat acetylation was demonstrated to be important
for transactivation [40, 41, 42, 131, 132, 133, 134, 135].
Unlike other transactivator, the capacity of binding to many cellular partners (DNA,
RNA, proteins) makes Tat as a key-player in HIV-1 life cycle [38, 39].Many HIV-1
Tat binding proteins have been isolated and characterized for their role in HIV-1 Tat
mediated transactivation [38, 142, 143, 144, 145, 146, 147, 148, 149, 150]. 5 HIV-1
Tat protein is the transcriptional transactivator for the LTR promoter and functions
by binding to the transactivation responsive region (TAR) element. The full-length
HIV-1 transcripted productions are stimulated by the binding of Tat to TAR [38, 39].
The Tat•TAR integrity determines the dynamics of viral replication in infected cells
[38, 39]. Mujtaba et al. showed that PCAF bromodomain can compete against TAR
RNA for binding to lysine-acetylated Tat [45].
HIV-1 Tat contributes to various steps from chromatin remodeling to the end of
transcriptional elongation by the recruitment of a large number of cellular factors
[38, 39]. All studies have contributed to the elucidation of the different in vivo steps
of transcription and transactivation with HIV-1 Tat recruiting specific factors at
each step [38, 39]. Knowledge of the structure of HIV-1 Tat protein with its various
classes of post-translational modifications would be helpful for understanding the
alterations in transactivation, and therefore, for HIV-1 novel anti-retrovirus therapy.
In this thesis I have studied the interaction of HIV-1 Tat with PCAF bromodomain.
PCAF is a transcriptional coactivator and associates with p300/(CREB-binding pro-
tein) [151]. PCAF belongs to the GCN5/pCAF family of nuclear histone acetyltrans-
ferases (HATs) [152]. The HIV-1 full length Tat in complex with PCAF (Tat.PCAF)
5The interactions between HIV-1 Tat and the TBP [147, 149, 150], TFIIB [150], TFIIH [144,
146], Sp1 [143, 145, 148], and TAF55 [142] suggest a direct involvement of HIV-1 Tat in the early
steps of transactivation during the formation of the pre-initiation complex (PIC).
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is one of the crucial steps in recruitment of the components of a competent preinitia-
tion complex (PIC) by Tat and cellular factors [38, 39, 40, 46]. Tat•PCAF formation
requires acetylated lysine 50 in Tat (AcK50) and in turn, generates acetylation at
lysine 28 in Tat (AcK28-Tat) [38, 39, 42, 45, 153, 154, 155]. However, the structure
of full length of acetylated lysine HIV-1 Tat and PCAF has not yet been determined
experimentally.
The sequence of HIV-1 Tat and structure in unbound form and in complex with one
of its cellular partner, PCAF bromodomain are described in detail in Chapter 5.
2.5 Drug resistance and new strategies for drugs based
on IN and Tat
A wide variety of HIV-1 drugs have been pursued [4], see a summary on (Figure
2.3)). Nevertheless, they all face to the drugs resistant problems which is still a
major challenge for new therapies [52].
Difficulties in HIV-1 therapies also include[4, 156]: (i) the life-long duration of ther-
apy; (ii) the ultimate role of pre-exposure prophylaxis (PrEP); (iii) the drugs side-
effects or toxicity; (iv) the emergence of drug-resistance and high genetic diver-
sity; (v) the specter of new cross-species transmissions from established retroviral
reservoirs in apes and Old World monkeys; (vi) the continued pace of new HIV-1
infections in many parts of the world.
Current therapies, targeting on integrase, entry inhibitors, and viral processing, will
likely be useful for the treatment of antiretroviral-experienced patients. Several
promising new strategies might, at least in part, counteract viral hypervariability
[157, 158], which is responsible for drug resistance [157, 4]. In this respect, one of the
possible successful strategy is targeting HIV-1 protein/human protein interactions
[157, 4], since the human proteins cannot mutate such as viral ones [4, 5, 10, 12].
Hence, each step of the HIV-1 life cycle in which both viral proteins and human
proteins are involved can serve as a potential target for inhibition [4]. Among of
them, the reverse transcription and integration steps are relatively well understood
at the molecular level [159, 160]. HIV-1 IN was the most recent HIV-1 enzyme to
be successfully targeted for drug development [161, 162, 163]. In 2007, Raltegravir
(RAL, MK-0518) was approved by FDA, and other integrase inhibitors, including
Elvitegravir (EVG, GS-9137), are progressing through clinical development [164,
165]. However, resistance [166] and cross resistance problems between RAL and
EVG have already been reported [167].
Another possible target for anti-AIDS therapies is Tat, which plays a pivotal role
in HIV replication [168]. Tat, together with other regulatory genes, is more highly
conserved among the different types of the HIV virus found worldwide than are other
HIV-1 genes [169]. Moreover, Tat is released by infected cells and instructs cells in
close proximity to become more prone to infection [168, 169]. These features make
the Tat protein an excellent candidate for vaccine development. Recently, an analog
of the natural steroidal alkaloid cortistatin a potently was shown to suppress Tat-
dependent HIV-1 transcription [170]. Finally a class of novel small molecules has
been developed and effectively inhibited the PCAF bromodomain association with
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Figure 2.3 Illustration of current targets for antiretroviral drugs, number
labeled according to the steps in HIV-1 life cycle. (A) HIV-1 life cycle (B)
Preclinical, abandoned (normal text), FDA-approved (bold text) inhibitors are listed
in relation to specificity of action and drug target. The figure B is adapted from Arts
et al., Cold Spring Harb Perspect Med 2012 [4]. NNRTI stands for non-nucleoside
reverse transcriptase inhibitors. NRTI stands for nucleoside reverse transcriptase
inhibitors.
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AcK50-Tat in vitro [171]. To date, the inhibitors for Tat activation or Tat•PCAF
interactions have not been clinical tested. The first phase of clinical testing of
preventive vaccine against HIV-1 infection based on the association of the Tat protein
and the Env protein has been launched by The National Center of the Istituto
Superiore di Sanita, Italy [169]. The Tat vaccine is already advanced to therapeutic
phase II trials in Italy and South Africa [169].
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3
Materials and Methods
In this thesis work, I use three main computational approaches: (i) structural bioin-
formatics, (ii) protein - protein docking, and (iii) molecular dynamics simulations.
Hence, I report in detail for each of these approaches in the following sections.
3.1 Structural bioinformatics
The three dimensional (3D) structure of proteins can provide crucial insights into
their mode of action. However, the number of sequenced genomes is growing faster
than the number of experimentally resolved protein structure [172]. For example,
the number of protein sequences in NCBI protein database is currently almost 15
millions (http://www.ncbi.nlm.nih.gov/RefSeq/) and in UniProt is more than 21
millions (http://www.ebi.ac.uk/uniprot/TrEMBLstats/); in contrast, the number
of protein structure on PDB is less than 100,000 (http://www.pdb.org/). Indeed,
the structures of less than 1% of the sequences have been experimentally determined
[173]. Computational Structural Biology (CSB) methods can predict protein struc-
tures by sequence-based and / or structure-based approaches. Hence, computational
methods are continuously growing of importance in structural biology [174].
In CSB, the unknown structure of a protein can be predicted by giving a structurally
resolved protein(s) as template(s) with roughly 30% or more sequence identity (SI)
[174]. As expected, the predictions increase their reliability with higher SI [175].
Hereby, I will provide a brief introduction to biological databases, especially protein
databases, focusing on those databases used in this thesis for the studies of the
protein-protein interactions and for the homology modeling and docking steps. Next,
I will describe the methods used in this thesis, including multiple sequence alignment
and homology modeling.
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3.1.1 Biological Databases:
3.1.1.1 Protein Sequence Databases
A protein sequence database is a large collection of amino acid sequences stored in a
computer and coming from several resources, including translations from annotated
coding regions as well as records from protein motif/structure databases.
Protein Data Bank (http://www.ncbi.nlm.nih.gov/protein), SwissProt (http://www.
ebi.ac.uk/uniprot/), PIR-PSD (http://pir.georgetown.edu/) and PRF (http://www.
prf.or.jp/index-e.html) are among the well-known protein sequence databases. There
are different types of sequence databases, basically grouped into two categories: se-
quence repositories, in which data are stored with little or no manual intervention
in the creation of the records; and expertly curated databases, in which the original
data are enhanced by the addition of further information [176]:
Sequence repositories: These databases contain redundant records of protein
sequences, but they store not much information about the sequences. Some examples
are: GenPept by the National Center of Biotechnology Information (NCBI) [177],
NCBI’s Entrez Protein with the translated sequences from other resources, RefSeq
(http://www.ncbi.nih.gov/RefSeq) with a non-redundant collection of the protein
sequences.
Universal curated databases: Additional information and annotations are added
to the protein sequences archived in these databases, in order to make the research
easier for the users. They are the Protein Information Resource-Protein Sequence
Database (PIR-PSD) - (http://pir.georgetown.edu/), Swiss-Prot - the leading uni-
versal curated protein sequence database (http://www.ebi.ac.uk/swissprot/index.html),
TrEMBL - a fully curated Swiss-Prot entry; UniProt - a combination of the Swiss-
Prot, TrEMBL and PIR-PSD databases.
3.1.1.2 PDB: Protein Data Bank
The Protein Data Bank (PDB) is the largest worldwide repository of information
about the 3D structures of large biological molecules, including proteins and nucleic
acids (http://www.rcsb.org/pdb/home/home.do) [178]. PDB currently hosts 83,106
structures, obtained by X-ray, NMR, electron microscopy or hybrid methods (Table
3.1).
3.1.1.3 PROSITE: Protein Database
PROSITE [179] is the database of biologically significant sites and patterns. It
can rapidly and reliably identify which known family of proteins (if any) the new
sequence belongs to (http://prosite.expasy.org/). If the sequence of an unknown-
function protein is far from any other protein, its function could be identified by the
occurrence of a particular cluster of residue types in its sequence, which is variously
known as a pattern, motif, signature, or fingerprint. This information is stored in
PROSITE database.
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Table 3.1 PDB current holdings’ breakdown
(http://www.rcsb.org/pdb/home/home.do).
3.1.1.4 HIV-1, Human Protein Interaction Database
The HIV-1 and human protein interaction data presented in this database (http://www.
ncbi.nlm.nih.gov/RefSeq/HIVInteractions/) [180, 181, 182] are based on literature
reports. The HIV-1 proteins and theirs interactions are reported and the users can
browse this information based on the name of the proteins. The two target proteins
in this thesis are the so-called ”tat” and ”integrase” proteins stored in ”tat” and ”pol”
parts. There are 125 and 1,690 interaction records for the integrase and tat proteins,
respectively.
3.1.2 Multiple sequences alignment (MSA)
3.1.2.1 Background and Theory
The multiple sequence alignment is the starting point for any structural prediction
method based on homology modeling. A sequence alignment allows a researcher to
identify one or more sequences (with known 3D structures) with sufficient similarity
to the target protein (with unknown structure) to be employed in a homology mod-
eling procedure [183]. The similarity is measured through the number of identical
residues between sequences. An optimal alignment is operationally defined with the
highest alignment score for a given scoring scheme. The scoring schemes or weight
matrices that may be applied to alignment are grouped into four categories [184]:
(i) Identity Scoring: This is the simple scoring scheme. Amino acid pairs are
scored with a positive value, typically one, if they are identical and with zero
otherwise. This scoring scheme is generally considered less effective than the
other schemes that weight non-identical pairs, particularly for the detection of
weak similarities [185, 186, 187].
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(ii) Genetic Code Scoring: Genetic Code Scoring was introduced by Fitch in 1966.
It considers all amino acid transitions with equal weight [174, 188] and the
minimum number of DNA/RNA base changes (0, 1, 2 or 3) that would be
required to interconvert the codons that code one sequence into the other.
(iii) Chemical Similarity Scoring: Twenty amino acids pairs can be weighted dif-
ferently in the alignment procedure according to the similar physico-chemical
properties. This is how the Chemical Similarity Scoring works. This is de-
sirable since major changes in amino acid type could reduce an capability of
the protein to perform its biological role and hence it is probable that such
changes do not fold in a similar structure. The scheme was initially invented
by McLachlan [189] and then developed by Feng et al. [187].
(iv) Observed Substitutions: This scoring scheme is based on the observed fre-
quencies of such occurrences in alignment of evolutionary related proteins.
The scheme-alignment is likely a chicken-egg problem, a scoring scheme is
needed for alignment and in order to derive a scoring scheme, an alignment is
needed[184, 184]. In this thesis, I mainly adopted this kind of scoring scheme.
Therefore, here I describe this approach in more details.
The scoring scheme above mentioned is usually represented by a matrix of numbers
whose entries provide a measure of the alignment between each of the possible amino
acid pairs [186]. The observed substitution matrices were firstly used by Dayhoff
et al. [186]. Nowadays, there are several types of commonly used substitution
matrices: PAM, BLOSUM, GONNET, DNA Identity and PUPY [190] matrices.
Our sequence alignments are based on PAM45 and BLOSUM62 matrices and hence
a briefly description of the methods behind them is provided.
PAM (Point Accepted Mutation): The first substitution matrices to gain
widespread usage were those based on the PAM model of evolution [186]. PAM
matrix is derived from global alignment of very similar sequences (at least 85% iden-
tity). Different PAM matrices are identified by a number, for example PAM120
and PAM90, which refers to the ”evolutionary distance”: the larger the number,
the larger the distance. PAM250, for example, means that about 250 mutations
per 100 amino acids may have happened, while with PAM10 only 10 mutations per
100 amino acids are assumed, so that only very similar sequences will reach useful
alignment scores.
BLOSUM (BLOcks SUbstitution Matrix) matrices [191] are derived by ana-
lyzing local multiple alignments of more distantly related sequences. Firstly, all the
sequences in BLOCKS database [192] are collected and used to search for conserved
blocks. The second stage is counting the pairs of amino acids in each column of
the multiple alignment. For example, in a column with the amino acids AAGACA,
there are 6 AA pairs, 4 AG pairs, 4 AC, and one GC. The probability qij for a pair of
amino acids in the same column to be i and j is calculated, as well as the probability
pi of a certain amino acid to be i. In the third stage the log-odds ratio is calculated
as
Sij = log2
qij
pi
(3.1)
The value 2Sij is then stored in the ij entry of the BLOSUM matrix.
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The different BLOSUM matrices are identified by a number, which denote the level
of clusterization: for example, BLOSUM62 matrix is derived by taking into account
sequence blocks clustered with a 62% of identity level. Figure 3.1 shows the BLO-
SUM45 matrix, a popular substitution matrix for amino acids.
Figure 3.1 The BLOSUM45 matrix, a popular substitution matrix for amino acids.
Figure is adapted from [174].
3.1.2.2 Gap Penalties
It is desirable to allow some gaps to be introduced into an alignment to compensate
for insertions and deletions done by evolution but not so many that the alignment
asserts an implausible series of molecular alterations. This is accomplished by de-
ducting some amount from the alignment score for each gap introduced, the so-called
gap opening. Although a number of strategies have been proposed for penalizing
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gaps, the most common formulation, known as affine gap penalties, involves a fixed
penalty for introducing a gap, plus an additional penalty proportional to the length
of the gap [183]. Most programs allow the user to choose these penalties, which may
have different optimal values for different systems. The optimal values also depend
on the scoring matrix used.
3.1.2.3 Multiple Sequence Alignment (MSA) Programs
MSA is generally the sequence alignment of three or more biological sequences (pro-
tein, or nucleic acid) of similar length. A common approach to multiple sequence
alignment is to progressively align pairs of sequences. The general progressive strat-
egy can be outlined as follows: a starting pair of sequences is selected and aligned,
then, each subsequent sequence is aligned to the previous alignment. The most
common algorithms [183] used for such a progressive sequence alignment are the
Needleman-Wunsch [193] and Smith-Waterman [194] ones.1
Many parameters affect the result of a multiple sequence alignment, such as obviously
the scoring matrices and the gap penalties associated with the pairwise alignment
steps. The pairwise alignment parameters described in the previous section have the
same meaning in the multiple alignment. Another parameter is the delay divergent
sequence control which delays the alignment of the most distantly related sequences
until the most closely related sequences have been aligned.
I will describe the sequence alignment programs used in this thesis.
• ClustalW: [191, 195, 196] The heuristic used in ClustalW is based on phylo-
genetic analysis. Firstly, a pairwise distance matrix for all the sequences to be
aligned is generated, and a guided tree is created using the neighbor-joining
algorithm [197]. Then, each of the most closely related pairs of sequences -
the outermost branches of the tree - is aligned to each other using dynamic
programming[198, 199]. Next, each new alignment is analyzed to build a se-
quence profile. Finally, alignment profiles are aligned to each other or to other
sequences (depending on the topology of the tree) until a full alignment is
built.
This strategy produces reasonable alignments under a range of conditions. It’s
not foolproof: for distantly related sequences, it can give bad results due to the
inaccuracies of the pairwise alignment and the phylogenetic analysis. But for
sequence sets with some recognizably related pairs, it can produce very good
outcomes based on the strengths of these methods. The pairwise sequence
alignment by dynamic programming is accurate for closely related sequences
regardless of which scoring matrix or penalty values are used. Phylogenetic
analysis is relatively unambiguous for closely related sequences. Using multiple
1Needleman-Wunsch and Smith-Waterman are heuristics algorithms, i.e. experience-based al-
gorithms. One heuristic algorithm uses pairwise alignments between every pair of sequences and
combines them together in a way that pairwise alignments induced by the multiple alignment are
close to the optimal ones. However, it is not always plausible to combine optimal pairwise alignment
to MSA. Then, a greedy heuristic algorithm is used to construct a global alignment by aligning the
two most similar sequences, and then adding the other sequences one by one.
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sequences to create profiles increases the accuracy of pairwise alignment for
more distantly related sequences.
One of ClustalW’s paradigms is that, in protein sequence alignment, different
scoring matrices have to be used for each alignment based on the expected
evolutionary distance between the two sequences. If the two sequences are
close neighbors in the tree, a scoring matrix optimized for evolutionary close
related sequences aligns them. Distant neighbors are aligned using matrices
optimized for distant relationships. In our studies I chose BLOSUM62 for
closer sequences and BLOSUM45 for more distant relationships, rather than
the same scoring matrix for all pairwise alignments.
Another paradigm of ClustalW is the use of scalable gap penalties for protein
profile alignment. A gap opened next to a conserved hydrophobic residue can
be penalized more heavily than a gap opened next to a hydrophilic residue. A
gap opened too close to another gap can be penalized more heavily than an
isolated gap.
• TCOFFEE: [200, 201, 202, 203] TCoffee is based on the popular progressive
approach [203] to multiple alignments but it avoids the most serious pitfalls
caused by the “greedy nature” of this algorithm. A data set of all the pairwise
alignments between the sequences was pre-processed and this information is
used to guide the progressive alignment. Intermediate alignments are based
not only on the sequences to be aligned but also on how all the sequences
align with each other. This alignment information can be derived from het-
erogeneous sources such as a mixture of alignment programs and/or structure
superposition. TCoffee shows a high accuracy comparing to other MSA pro-
grams, especially in case of low level of average identity [200].
• MUSCLE: [204, 205] MUltiple Sequence Comparison by Log- Expectation
(MUSCLE) follows a guided tree construction; the fundamental step is the
pairwise profile alignment, which is used first for progressive alignment and
then for refinement. MUSCLE creates alignments with average accuracy com-
parable with or superior to the best current methods [204].
3.1.3 Homology Modeling
3.1.3.1 Introduction
Homology modeling is a computational methodology to assign a 3D structure to
a target protein when experimental data are not available. The methodology uses
another protein with a known structure that shares some sequence identity with the
target as a template [206]. An overview of the relationships between the percentage
of sequence identity target-template and the information achievable with homology
models is shown in Figure 3.2. The higher the sequence identity, the more accurate
the resulting structure information. Normally, models coming from 3D structures of
sequences with at least 50% sequence identity can be used for drug design purposes
[207].
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Figure 3.2 The correlation between the percentage of sequence identity target-
template and the typical information that can be retrieved through homology models
(adapted from [208]). Sequence identity between target and template sequences is
shown in the first bar. The second bar indicates the methods can be used to detect
sequence similarity between target and template sequences. The third bar shows
some available applications of the homology modeling.
3.1.3.2 Methods
To predict the structure of a sequence by homology modeling, typically a multistep
process is employed, that can be summarized in the following seven steps:
(1) Template recognition and initial alignment: The first step is to identify
protein structures related to the target sequence (the sequence whose 3D struc-
ture we want to predict), and then to select those structures that will be used
as templates. Numerous protein sequence and structure databases as the ones
described in Section 3.1.1 are employed in this step. The most used database
search engines for this step are: Basic Local Alignment Search Tool (BLAST)
[209], FASTA [210, 211] and Position-Specific Iterative Basic Local Alignment
Search Tool (PSI-BLAST) [212]. PSI-BLAST is based on multiple iterations. Its
iterative profile generation process makes PSI-BLAST far more capable of de-
tecting distant sequence similarities than a single query in, for example, BLAST,
because it combines the underlying conservation information from a range of re-
lated sequences into a single score matrix. Evolution could have conserved 3D
protein structures even after considerable erosion of their sequence similarity.
PSI-BLAST has demonstrated to be useful in detecting such relationships via
sequence searches, which were previously detected only through direct compar-
ison of 3D structures [212]. Structural information of proteins including coordi-
nates, sequences and motif are stored in PDB [178], SCOP [213], DALI [214] and
CATH [215] databases. The probability of finding a related protein of known
structure for a sequence picked randomly from a genome ranges from 20% to
70% [216, 217, 218, 24, 219].
There are two types of matrices mainly used by BLAST (PSI-BLAST) or FASTA
[220] for their alignment procedures: residues exchange and alignment matrix.
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(i) Residue exchange matrix (Figure 3.3): The elements of this 20 x 20 matrix
are related to the likelihood that two of the 20 natural amino acids can be
aligned. Therefore, the values along the diagonal (representing conserved
residues) are the largest ones, however, the exchanges between residues
with similar physico-chemical properties get a better score than exchanges
between residues that widely differ in their properties. For example, the
score between Lysine (K) and Arginine (R) in the matrix of Figure 3 is 2,
but between K and Phenylalanine (F) is -3.
(ii) Alignment matrix: Alignment matrix has a size that corresponds to the
number of residues of the two sequences to be aligned and the matrix
elements are simply the values from the residue exchange matrix for a given
pair of residues. During the alignment process, the different algorithms try
to find the best path through this matrix, starting from a point near the
top left, and going down to the bottom right as the diagonal with largest
score.
Figure 3.3 A typical residue exchange or scoring matrix used by alignment algo-
rithms. Figure is adapted from Elmar Krieger et al. [220].
(2) Alignment correction: A subset of the results obtained from the previous
step is selected as possible modeling templates through a multiple sequence
alignments (MSA). Maximal care has to be taken in this step to get the most
accurate alignments: in fact, there is no homology modeling program or tool
that can provide good results from an incorrect alignment [221]. Therefore, the
knowledge about the family and the structure of homologous proteins to be used
as possible templates can help in this phase to reasonably adjust the alignments.
(3) Backbone generation: The actual model building can start from the MSA
results by simply copying the backbone coordinates of the template residues
to the aligned sequence of the target. If two aligned residues differ, only the
backbone coordinates (N, Cα, C and O) can be copied. If they are the same,
one can also include the side chain (at least the more rigid side chains, since
rotamers tend to be conserved) [220]. In case the templates are not so good, for
example, low resolution for X-ray structures or low number of NOE for NMR
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structures, the determined region of the target can be chosen from the template
with the fewest errors [220]. In particular, in these cases multiple templates can
improve the quality of homology models [222].
(4) Loop modeling: During the MSA, gaps are introduced, either in the model
sequence (deletions) or in the template sequence (insertions). This implies a
conformational change of the building backbone and can result in loops or turns.
To model a loop different methods can be employed according to the kind of
protein and the length of the loop. With short loops, (∼ 5-8 amino acids), the
ones we are more interested in this thesis, several methods have been proved to
provide accurate results.
In particular, there are three main approaches for short loop modeling: (i) the
database-search approach that scans a database with all known protein struc-
tures to find segments fitting the sequence [223, 224] (ii) the conformational-
search approach that relies on an optimization of a scoring function [225, 226,
227] or (iii) hybrid methods which combine the two above-mentioned approaches
[228, 229].
(5) Side-chain modeling: As already mentioned, if the residues are conserved, the
side-chain conformations (rotamers) can be simply copied from the templates.
In the real case, especially when gaps are introduced, all successful approaches
to side-chain building are at least partly “knowledge-based”, i.e. they employ
rotamers libraries obtained by high resolution X-ray structures [220].
Some of the homology modeling programs focuses on improving the side-chain
modeling; among these, SCWRL4 [230] has recently proved to provide very good
results in this step. It is based on a new algorithm that improves accuracy at
reasonable speed. This result has been achieved through: (i) a new backbone-
dependent rotamer library based on kernel density estimates; 2 (ii) averaging over
different conformations in the rotamer library; (iii) a fast anisotropic hydrogen
bonding scoring function; (iv) a short-range, soft van der Waals atom-atom in-
teraction potential in the force field employed in the minimization step; (v) fast
collision detection using k-discrete oriented polytopes; (vi) a tree decomposition
algorithm to solve the combinatorial problem; and (vii) optimization of all pa-
rameters by determining the interaction graph within the crystal environment
using symmetry operators of the crystallographic space group.
(6) Model optimization: The above-mentioned corrections on the backbone and
side-chain have a large impact in the accuracy of the models. In fact, to predict
the side-chain rotamers with high accuracy, we need the correct backbone and
vice-versa. Therefore, it is an iterative process to obtain the optimal model: one
starts by predicting the rotamers, then one calculates the shifts in the backbone,
then one gets the rotamers for the new backbone and so on until the procedure
converges.
This iterative procedure cannot work if a very accurate energy function (force
field) cannot be employed in the energy minimization step that allows find-
2A kernel is here defined as a non-negative symmetric function, such as a Gaussian, that inte-
grates to 1.0 and is centered on each data point. Density estimates at specific query points are
determined by summing the values of the kernel functions centered on the data points [231, 232]
3.1. Structural bioinformatics 27
ing the new atomic positions. To this aim, quantum force fields3 [233] or self-
parameterizing force fields [234, 235] can be used.
Nowadays, thanks to the advances in high computing, quantum force fields are
more and more feasible and provide the best accurate descriptions of the charge
distributions of these kind of systems [233]. In these cases, if large computational
resources are available, the most straightforward and modern approach to the
model optimization is then to run a molecular dynamics simulation of the model.
Such a simulation describes the motion of the protein on a femtosecond (10−15
s) timescale and approach the folding process [220].
(7) Model validation: The evaluation of the models is critical for testing and se-
lecting the best and most accurate models. Modeling programs often offer some
scoring for the evaluation of the quality of the models generated. The validation
can be based on energetic calculations or on experimental data [184]. Among
the most commonly used approaches, I employed PROSAII [236] for evaluating
the model fold and PROCHECK [237] for checking the model’s stereochemistry.
PROSAII is based on a mean force potential that describes the free energy of
interaction between atoms or residues. PROCHECK provides some evaluations
of the model’s stereochemistry such as Ramachandran plot, residues properties,
main chain bond length / angle distributions, distorted geometry plots, etc.
Among this information, the Ramachandran plot is often the most informative.
It shows the distributions of the torsional angles - phi (φ) and psi (ψ) - in the
peptidic bonds of the residues [238] stereochemistry.
3.1.3.3 Homology modeling by MODELLER
There are various tools available to the scientific community for homology model-
ing, such as SWISS-MODEL [239, 240], WHATIF [241], COMPOSER [23, 242, 243,
244, 245], CONGEN [246], InsightII/Homology [247], ICM-Homology [248] which
uses rigid body superposition, Look/GeneMine with the segment matching [249],
MODELLER [22, 22, 25, 221] and InsightII/Modeler [23] that adopt the spatial
restraints concept. MODELLER is perhaps the most widely used structure predic-
tion program [250] (http://salilab.org/modeller) and it supports also the modeling
of non-standard amino acids. Many of the strongest performing prediction servers
in the CASP8 4 experiment, such as HHpred, incorporate MODELLER in their
methodology [251, 252]. In this thesis, MODELLER has been used for homology
modeling of proteins’ 3D structures.
Alignments between amino acid sequences become difficult in the “twilight zone”
of less than 30% sequence identity [207]. However, the active sites can have very
similar geometries, even for distantly related proteins [253, 254]. Multiple templates
from MSA and templates detected by PSI-BLAST [212] may improve the quality
3Nowadays, it is plausible to apply methods of quantum chemistry to entire proteins, arriving at
more accurate descriptions of the charge distribution [233]. In these quantum force fields, energies
are expressed as a function of the positions of the atomic nuclei only.
4CASP stands for The Critical Assessment of methods for protein Structure Prediction. CASP
experiments aim at establishing the current state of the art in protein structure prediction, identi-
fying what progress has been made, and highlighting where future effort may be most productively
focused. There have been nine CASP experiments so far, updated every two years since 1994.
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of the model [222] as described before. Multiple templates could be used to build
a consensus scaffold, in particular to build loops and other ambiguous fragments of
the target putative structure. Alternatively, a set of distance restraints could be
extracted from the templates. A consensus model could then be built by means of
fit that better satisfies these restraints [23]. The latter is the approach employed by
MODELLER and the one applied in the case of HIV-1 integrase protein treated in
this thesis, in which one of the templates shares 33% sequence identities with the
HIV-1 integrase.
Homology models can be applied at various stages of the drug discovery process
(Figure 3.2) [255, 256]. In general, if the sequence identity between the target and
the templates is over 50%, the derived models are good enough for drug discovery
applications; for sequence identities between 25 and 50% the models can still be
used to assess target druggability or to design mutagenesis experiments; finally, for
sequence identities lower than 25% and in any case larger than 10%, any conclusion
can at most be considered [257].
3.2 Prediction the structure of Protein-Protein com-
plexes
3.2.1 Introduction
In this thesis I use computational docking approaches that aim at predicting and
characterizing the Protein - Protein Interactions (PPIs) at molecular and atomic
levels, starting from the structural determinants of the single moieties. There are
numerous docking programs [258, 259, 260]. All of all them them relies on two
complementary components: (i) conformational space searching algorithms and (ii)
a scoring function to evaluate the proposed binding modes referred to as poses [261].
Here I use the HADDOCK program, widely used already in our group and for which
there is therefore large expertise.
3.2.2 Data-driven docking by HADDOCK
3.2.2.1 Introduction
HADDOCK (High Ambiguity Driven protein-protein DOCKing) [262, 263] is a dock-
ing program that exploits experimental biochemical and biophysical data to pre-
dict the structures of the docked complexes. It has been used successfully in pre-
dicting a plethora of biomolecular complexes, especially protein-protein complexes
[17, 26, 264]. Unlike other ab initio docking methods, which are based on theoret-
ical knowledge, HADDOCK encodes the experimental information about identified
or predicted protein interfaces in the so-called Ambiguous Interaction Restraints
(AIRs) to drive the docking process. Through AIRs, HADDOCK constrains the
conformational search problem.
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3.2.2.2 Algorithm
The HADDOCK algorithm takes the 3D structures of the molecules to be docked
as input. Moreover, it uses other experimental data, rewritten as AIRs, as inputs to
guide the docking. These data could be chemical shift perturbations, mutagenesis
data, etc. (see for example Figure 3.4A,B). Such experimental data often provide
evidences about crucial contacts involving some residues close to the possible inter-
face and thus these residues are considered the driven-force for the docking. The
AIRs define a network of restraints between the possible interaction interface(s) of
the molecules to be docked without defining the relative orientation of the molecules
but largely decreasing the search through the conformational space needed to as-
semble the interfaces.
Figure 3.4 Mutagenesis data used to guide the docking between two proteins A
and B (figure A and B) and AIRs between two proteins (C).
There are two kinds of AIRs: the ones involving active and the ones involving passive
residues (Figure 3.4C). The active residues are the residues directly involved in the
interactions, and the corresponding AIRs are usually taken from NMR mutagenesis
data. The passive residues are all the other neighbor residues close to the interface.
All the residues involved in the AIRs should have high solvent accessibility (>50%).
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An AIR can be defined through the distances between any atom of an active residue
i of protein A and any atom of all active and passive residues x,y,z of protein B
(Figure 3.4C). The averaged distance calculated through the formula:
deffiAB =
NAatoms∑
miA=1
NresB∑
k=1
NBatoms∑
nkB=1
1
d6miAnkB
−1/6 , (3.2)
is called the effective distance. In (3.2), NAatoms and NBatoms are the number of
atoms in the given residue, NresB is the number of residues at the interface of the
target molecule B. The 1/d6 factor somehow mimics the attractive part of a Lennard-
Jones potential and ensures that the AIRs take effect only when any two atoms of
the biomolecules are in contact. The AIRs are incorporated as an additional energy
term to the energy function that is minimized during the docking (see next section).
The accessibility of each residue in the docked protein can be predicted based on
sequence conservation and other properties in absence of any experimental informa-
tion on the interaction surfaces. WHISCY web-server [265] (http://nmr.chem.uu.nl/
Software/whiscy/index.html) can be used, for example, for this purpose.
The protocol of HADDOCK consists of four steps:
(i) Topology and structure generation: CNS topologies and coordinates files
for the two or more molecules to be docked are generated by combination from
the ensembles of starting structures (the input PDB files).
(ii) Randomization of the starting orientation and rigid body energy
minimization: first of all, the initial structures will be separated 150 A˚ away
in space and each molecule will be randomly rotated around its center of mass.
Rigid body energy minimization is then performed: the first four cycles of
orientational optimization are performed, in which each protein in turn is only
allowed rotating to minimize the intermolecular energy function; then, two
cycles of rotational and translational rigid body minimization of the scoring
function (see next section) are performed and the two proteins are docked by
rigid body energy minimization.
(iii) Semi-flexible simulated annealing: the main structures from step (ii) (the
number is defined by user) undergo a semi-flexible simulated annealing (SA) in
torsion angle space. This step includes: high temperature rigid body search;
rigid body SA; semi-flexible SA with flexible side chains at the interface; semi-
flexible SA with fully flexible interface (both backbone and side chains are
allowed to move).
(iv) Flexible refinement in explicit solvent (water or DMSO): the structures
obtained from the previous step are refined by inserting them in an explicit
solvent layer (8 A˚ for water, 12.5 A˚ for DMSO) and performing an explicit
solvent minimization. At the end, a list of structures ranked by docking score
is generated.
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3.2.2.3 Scoring function
The docking scores or docking functions that docking programs minimize to find the
best poses is often a combination of various (empirical) terms such as intermolecular
van der Waals, intermolecular electrostatic, hydrogen bonding and buried surface
area energies. In particular, HADDOCK scoring functions for each step are defined
as
Rigid docking:
Score = 0.01 Eair + 0.01 EvdW
+ 1.0 Eelec + 1.0 Edesol − 0.01 BSA (3.3)
Flexible docking:
Score = 0.1 Eair + 1.0 EvdW
+ 1.0 Eelec + 1.0 Edesol − 0.01 BSA (3.4)
Docking in water:
Score = 0.1 Eair + 1.0 EvdW
+ 0.2 Eelec + 1.0 Edesol (3.5)
where Eair is the ambiguous interaction restraint energy, EvdW is the van der Waals
energy term, Eelec is the electrostatic energy, Edesol is the desolvation energy term
derived from atomic solvation sarameters and BSA is burried surface area [266].
3.3 Molecular Dynamics Simulations
3.3.1 Introduction
The aim of classical molecular dynamics (MD) simulations is to model the detailed
microscopic dynamical behavior of chemical, physical or biological systems. MD
simulations can be applied to sample the configurational space of the system, to
describe the thermodynamic properties of the system at equilibrium and to investi-
gate the dynamics of the system [267]. The atomic motion is regulated by the laws
of classical mechanics. Experiments can validate the calculated results and provide
criteria to improve the methodology.
3.3.2 Equations of motion
Let us consider a system of N atoms moving under the influence of a potential
function U . Atoms are described by their positions
~RN =
{
~R1, ~R2, . . . , ~RN
}
(3.6)
and momenta
~PN =
{
~P1, ~P2, . . . , ~PN
}
. (3.7)
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The potential is assumed to be a function of the positions only, U
(
~RN
)
.
The Hamiltonian H of this system is
H
(
~RN , ~PN
)
=
N∑
I=1
~P 2I
2MI
+ U
(
~RN
)
, (3.8)
where the first term is the kinetic energy. The force acting on atom I is derived
from the potential
~FI
(
~RN
)
= −
∂U
(
~RN
)
∂ ~RI
. (3.9)
The equations of motion are given by the Hamilton equations:
~˙RI =
∂H
∂ ~PI
=
~PI
MI
, (3.10)
~˙PI = − ∂H
∂ ~RI
= − ∂U
∂ ~RI
= ~FI
(
~RN
)
, (3.11)
from which we get Newton’s second law:
MI ~¨RI = ~FI
(
~RN
)
(3.12)
3.3.3 Statistical Ensembles
The equations of motion (3.12) are time reversible (invariant to the transformation
t → −t) and therefore, according to the Noether’s theorem, the Hamiltonian (3.8),
which corresponds also to the total energy in this case, is conserved in time:
∂E
∂t
=
∂H
(
~RN , ~PN
)
∂t
= 0. (3.13)
Statistical mechanics [268] connects the microscopic details of a system, as the ones
described by the equations of motion above, to the physical observables such as
equilibrium thermodynamic properties, transport coefficients, and spectra.
Statistical mechanics deals with statistical ensembles. A statistical ensemble is a
collection of copies of the same system in which each copy represents a possible
microstate which the real system might be in [269, 270]. To describe a statistical
ensemble one needs a small set of thermodynamic/statistical variables are constant
over all the ensemble, such as the energy (E), the temperature (T), the pressure (P),
volume (V), the particle number (N), or the chemical potential (µ). The microcanon-
ical ensemble, for example, is characterized by having constant N, V and E, and is
therefore called the NVE ensemble, as well. Other examples include the canonical or
NVT ensemble, the isothermal-isobaric or NPT ensemble, and the grand canonical
or µVT ensemble.
The thermodynamic variables that characterize an ensemble can be regarded as the
experimental control parameters that specify the conditions under which an exper-
iment is performed. Now, consider a system of N atoms occupying a container of
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volume V and evolving under Newtonian equations of motion. As we have seen in
the previous section, the total energy is constant. In addition, N and V are in this
case constant by hypothesis. Therefore, a dynamical trajectory (i.e. the positions
and momenta of all the particles over time) will generate a series of classical states
having constant N, V, and E, corresponding to a microcanonical ensemble. If the
dynamics allows the system to visit all the possible states in an infinite time (ergodic
hypothesis), then a time average over this trajectory would yield the same result as
a statistical average in the microcanonical ensemble. The ergodic hypothesis is be-
lieved to hold for all Hamiltonians that describes real physical systems. However,
in practice only a finite number of states (snapshots) can be generated by our nu-
merical MD simulation, and therefore this result can be only approximately true
and convergence tests have to be done in order to verify that our trajectory is long
enough to give converged averaged values.
Most of the biological experiments are performed at constant pressure (atmospheric
pressure) and temperature and not in NVE conditions. Therefore, to mimic the
typical conditions of biological matter, our simulations have to reproduce an NPT
ensemble. To this aim, the degrees of freedom of the system have to be coupled
to some thermostat and barostat to control the pressure and the temperature (see
section 3.3.7). There are several algorithms to mimic the effects of real thermostats
such as the Berendsen [271] or the Langevin dynamics [272]. The first scheme
devised to describe a dynamics controlled by a barostats was introduced by Andersen
within the framework of so-called extended system dynamics [273]. I will give a
more detailed description of thermostats and barostats algorithm at the end of this
chapter.
3.3.4 Potential energy functions
As we have seen in section 3.3.2, classical MD models interatomic interactions
through a potential energy function U
(
~RN
)
[268]. A MD simulation consists of
the numerical, step-by-step, integration of the classical equations of motion (3.12).
To perform that we need to calculate the forces
{
~FI
}
(equation (3.9)) acting on atom
I which are gradients of the potential energy U
(
~RN
)
. In biomolecular simulations,
the potential energy function is usually approximated by a simple functional form,
which is usually called force field. There are several force fields currently used in
biomolecular simulations, tuned to work with more or less large set of different bio-
logical matter, such as: AMBER [274, 275], Homans’ carbohydrate [276], CHARMM
[277], CVFF - consistent valence [278], etc. In this thesis I use the second generation
of AMBER force field [279]. The standard AMBER force field [274, 275] has been
parameterized to describe the proteins and nucleic acids. However, AMBER has
been widely used not only for proteins and DNA, but also for many other classes
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of chemical compounds, such as polymers and small molecules. AMBER force field
has the following functional form:
U
(
~RN
)
=
∑
b
Kb (b− b0)2 +
∑
θ
Hθ (θ − θ0)2 +
∑
φ
Vn
2
[1 + cos (nφ− φ0)]
+
N∑
I<J
εIJ
[(
R∗IJ
RIJ
)12
− 2
(
R∗IJ
RIJ
)6]
+
N∑
I<J
qIqJ
ε0RIJ
. (3.14)
First term (summing over bonds) represents the energy between covalently bonded
atoms. This harmonic (ideal spring) force is a good approximation near the equilib-
rium bond length, but becomes increasingly poor as atoms separate. Second term
(summing over angles): represents the energy due to the geometry of electron or-
bitals involved in covalent bonding. Third term (summing over torsions) represents
the energy for twisting a bond due to bond order (e.g. double bonds) and neighbor-
ing bonds or lone pairs of electrons. A single bond may have more than one of these
terms, such that the total torsional energy is expressed as a Fourier series.
The fourth and the last term represent the non-bonded energy between all atom
pairs and can be decomposed in the van der Waals and electrostatic contributions,
respectively.
3.3.5 Periodic boundary condition (PBC)
Let us consider 1000 atoms arranged in a 10 x 10 x 10 cube. Nearly half the
atoms are on the outer faces, and these boundary atoms will have a large effect on
the measured properties. Periodic boundary conditions (PBC) enable a simulation
to be performed using a relatively small number of atoms in such a way that the
atoms experience forces as though they were in a bulk solution. PBC helps to avoid
problems with boundary effects caused by finite size, and makes the system more
similar to an infinite one (the one we would like to describe in order that its statistical
averages resemble the averages at the thermodynamic limit), at the cost of possible
periodicity effects [280].
The original system box is called unit cell, all other cells are called images. A certain
care has to be taken when applying PBC to biological systems, in order to minimize
boundary effects. In particular:
(i) Since biological matter is not isolated, it is usually described embedded in
a solvent environment. A sufficient number of water layers must be used to
prevent self-interaction of a protein, i.e between protein copies in neighboring
images. There must be at least 3 water molecules between the protein and the
unit cell boundary, i.e distance of ∼10 A˚. This condition will create a minimum
water buffer of about 20 A˚ between protein images.
(ii) The linear size L of the unit cell must be more than twice the cutoff distance RC
(see more detail in the next section 3.3.6). This condition eliminates correlated
fluctuations that atoms may experience due to simultaneous interactions with
two images of a given particle.
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3.3.6 Ewald summation
The computation of the non-bonded interactions (terms 4 and 5 in equation (3.14))
is the most time-consuming in molecular simulations. When the periodic conditions
are employed, the sums in terms 4 and 5 of equation (3.14) are over an infinite
number of atom pairs.
The simplest way to overcome this problem is to cutoff the energy at some distances
RC . However, it has been shown that this simple truncation approach can only
be applied if the energy term that describes the interaction is “short-range”, i.e.
it decays to zero with the distance between two atoms RIJ faster than R
−3
IJ [268].
Therefore, we can only cutoff the van der Waals potential (the 4th term in (3.14)5)
since it decays as R−6IJ , but we cannot this approach with the electrostatic potential
(the last term in (3.14)) that decays as R−1IJ .
Under the periodic boundary conditions, the electrostatic term can be rewritten as
U ele =
∑
~n
N∑
I<J
qIqJ
ε0
∣∣∣~RIJ + ~n∣∣∣ , (3.15)
where the first summation is over all periodic images and the second one over all
atom pairs in the unit cell.
The Ewald summation method [268, 281] and its variants are the most widely used
approaches in molecular dynamics simulations to compute equation (3.15). In this
method, first each point charge qI can be expressed as a charged density:
ρI
(
~R
)
= qIδ
(
~R− ~RI
)
. (3.16)
via the delta function δ
(
~R− ~RI
)
. Then, a Gaussian charge distribution ρGI of equal
magnitude and opposite sign is added at each point charge qI
ρGI = qI
(
α√
pi
)3
exp
(
−α2
∣∣∣~R− ~RI∣∣∣2) . (3.17)
The electrostatic potential due to both (3.16) and (3.17) becomes
US =
∑
~n
N∑
I<J
qIqJ∣∣∣~RIJ + ~n∣∣∣erfc
(
−α2
∣∣∣~R− ~RI∣∣∣2), (3.18)
where
erfc(x) =
2√
pi
x∫
0
e−y
2
dy. (3.19)
US is the short-range interaction potential according to the above definition and can
be, therefore, cutoff at a distance larger than RC . Finally, to recover the original
5A constant correction term is usually added to the potential term to take into account the
error done by neglecting all the interactions with the atom at a distance grater than RC and this
correction term is calculated by assuming a uniform distribution of the atoms over RC .
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charge content {qI}, a charge distribution −ρGI
(
~R
)
must be added. The potential
due to this change distribution can be expressed as a lattice sum in the reciprocal
space minus a self-term:
Um =
1
piV
N∑
I<J
qIqJ
∑
~k 6=0
1
k2
exp
(
− k
2
4α2
)
exp
(
i~k ~RIJ
)
− α√
pi
∑
I
q2I . (3.20)
where
−→
k = 2piL−1 (lx, ly, lz) and (lx, ly, lz) are integers. The parameters α can be
tuned to optimize converge properties of both summations (3.18) and (3.20).
Summarizing:
U ele = US + Um, (3.21)
where US is calculated in the direct space of the r’s while Um is calculated in the
reciprocal space of the k’s.
The Ewald summation method scales as N3/2 with respect to the total number of
atoms N in the system’s box. Therefore, it becomes prohibitively expensive for very
large systems as the one usually met in biophysics. To overcome this limitation, Tom
Darden et al. [?] introduced an approximated variant called the Particle Mesh Ewald
(PME) method, which scales as N log(N). In this method, the direct sum(3.18) is
still evaluated explicitly using the cutoff scheme while the reciprocal sum (3.20) is
approximated by using a Fast Fourier Transformation (FFT) algorithm with con-
volutions on a regular grid of points whose charges are interpolated from the real
charges in the system.
3.3.7 Thermostat and Barostat
As mentioned in Section 3.3.3, we need to apply thermostats and barostats to achieve
NPT condition. In this thesis work, I have used the Langevin thermostat to control
the constant temperature and Berendsen barostat to control the constant pressure.
3.3.7.1 Langevin thermostat
In thie Langevin thermostat approach [272], the stochastic Langevin equation of mo-
tion is integrated in place of the Newton’s equation of motion (3.12). The Newton’s
equation can be extended into the Langevin equation by adding a frictional force
and a random force term to the force derived from potential energy. Namely, the
Langevin equation of motion is given by
MI ~¨RI(t) = ~FI
[
~RN(t)
]
− γI(t)MI ~˙RI(t) + ~FRANI (t), (3.22)
where γI is the atomic friction coefficient, and ~F
RAN
I is the random force. The ran-
dom force put energy into the system whereas the frictional term removes (kinetic)
energy from the system.
The random forces ~FRANI (t) must have the following properties [282].
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(i) They are uncorrelated with the velocities ~˙RI(t
′) and the deterministic forces
~FI(t
′) at previous time t′ < t.
(ii) Their time averages are zero.
(iii) Their mean-squared components are equal to〈
~FRAN
2
I
〉
= αµIγIkBT0, (3.23)
where T0 is the reference temperature.
(iv) Random forces acting on different atoms and at different time are uncorrelated〈
~FRANI (t)~F
RAN
J (t
′)
〉
= δIJδ(t− t′). (3.24)
It can be shown that [282] the trajectory generated by integrating the Langevin
equation of motion corresponds to a canonical (NVT) ensemble at the temperature
T0.
3.3.7.2 Berendsen barostat
The Berendsen barostat [271] is based on the rescaling of the atomic positions and
the box size.
The pressure is given by
p =
2
3V
(EK − Ξ) , (3.25)
where Ξ is the internal virial
Ξ = −1
2
∑
I<J
~RIJ ~FIJ , (3.26)
if we consider the system is cubic and V = L3. The Berendsen barostat uses a
scaling factor, µ, which is a function of p, to scale the atomic positions and the box
lengths:
~RI → µ~RI , (3.27)
L→ µL. (3.28)
µ is given by
µ =
[
1− ∆t
τp
(p0 − p)
]1/3
, (3.29)
where ∆t is the time step, τp is the coupling constant, p0 is the target pressure. To
do so, an extra term is added to the equations of motion so as to achieve the pressure
change
dp
dt
=
p0 − p
τp
. (3.30)
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3.3.8 Energy minimization
Before starting a MD simulation, it is a desirable practice to bring the initial struc-
ture to a local potential energy minimum. This is mainly done to avoid bad contacts
between close atoms that may lead to unstable MD simulations. Various energy min-
imization algorithms have been devised to this aim. In this thesis, I have used the
steepest descent and conjugate gradient methods to carry out energy minimization.
3.3.8.1 Steepest Descent
The steepest descent [283] is the simplest minimization algorithm. It uses the gra-
dient of the function to direct the minimization process toward the nearest local
minimum. In this method, one iterates the following equation until it converges or
until it reaches a predefined maximum number of steps:
~RkI = ~R
k−1
I + λk
~SkI , (3.31)
where ~RkI is the new position of atom I at step k,
~Rk−1I is the position at the previous
step (k − 1), λk is the size of the step to be taken at step k and ~SkI is the direction
of that step. ~SkI is taken to be the opposite of the gradient of the energy function
with respect to ~RI :
~SkI = −~∇IU
({
~RkI
})
, (3.32)
while λk is adjusted at each iteration step: if the energy of the new conformation
is lower than that of the previous one, the algorithm assumes that the approaching
direction is correct and increases the step size λk by a small factor (often 1.2) to
improve efficiency; however, if the energy of the new conformation is higher, which
indicates that the real path has moved away from the current minimization direction,
the step size λk is decreased (often by the factor 0.5) to allow the algorithm to correct
the direction more efficiently.
3.3.8.2 Conjugate Gradient
The conjugate gradients method [283] exploits its “memory” of the gradients calcu-
lated in previous steps. The first step is taken in the direction of the force
~S1I = −~∇IU
({
~R1I
})
. (3.33)
but for all subsequent iterations, k > 1, the direction of the minimization step is
determined as a weighted average of the current gradient and the direction taken in
the previous iteration:
~SkI = −~∇IU
({
~RkI
})
+ bkI ~S
k−1
I , (3.34)
where
bkI =
∣∣∣~∇IU ({~RkI})∣∣∣2∣∣∣~∇IU ({~Rk−1I })∣∣∣2 . (3.35)
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The conjugated gradients method converges usually much better than steepest de-
scent one but it is less efficient than the steepest descent method to find the initial
minimization direction. For this reason, it is a common practice to start the mini-
mization procedure with the steepest descent algorithm and swap to the conjugated
gradients one after a certain number of steps. Another disadvantage of the con-
jugated gradients method is that the errors in the calculation of the gradients are
accumulated along the way. This problem is usually overcome by restarting the
minimization process often, after a given number of iteration steps.
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HIV-1 Integrase Binding to Cellular
Prolyl-Isomerase Pin1
Abstract
Viral cDNA integration into the infected cell genome is an essential step in the HIV-
1 life cycle. Hence, the viral integrase enzyme has become an important target for
antiviral therapy. Here we present a structural prediction of the complex of HIV-
1 integrase with one of its cellular partners, the human prolyl-isomerase-1 (hPin1)
enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases
integrase stability (Manganaro et. al. 2010, Nat. Med. 16, 329). Our structural
models are built on the basis of previous experimental observations. Some of the
predicted residue-residue interactions at the HIV-1 integrase•hPin1 interface are
then verified experimentally. Upon binding to hPin1, the catalytic core of the enzyme
remains unaffected while the mutual configurations of the protein domains rearrange.
Our structural investigation provides a rationale for the effect of mutating charged
residues at the protein surface, which are known to hamper virus replication in vivo
without significantly affecting integrase enzymatic activity; according to our models,
these residues form key interactions with hPin1. Mutation of these residues is likely
to affect HIV-1 integrase•hPin1 interactions and hence integrase stability in vivo.
4.1 Introduction
The HIV-1 pol gene encodes three enzymes, integrase (HIV-1 IN), protease (HIV-1
PR) and reverse transcriptase (HIV-1 RT). The antiretroviral drugs first targeted
HIV-1 RT and HIV-1 PR [4, 284]. The currently widely prescribed combination
antiretroviral therapy (cART) involves the use of different drugs targeting both en-
zymes [285], with the result of lowering viral loads. Despite the success of cART in
maintaining the disease asymptomatic for prolonged periods of time, this therapy
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has no effect on the latent reservoir of the virus [285]. Additionally, escaped mutants
often evolve under the selective pressure imposed by the drugs, facilitated by the ex-
tremely high mutation rate of the viral genome during viral replication. To overcome
these problems, over the last few years a number of drugs binding to targets other
than HIV-1 PR and HIV-1 RT have been developed. One of these targets is HIV-1
IN [4, 161, 162, 163]. Two inhibitors of this enzyme (raltegravir and elvitegravir)
have been successfully tested in clinical trials; the former was approved for clinical
use in 2007 [4, 286].
After reverse transcription of the genomic RNA into a DNA copy, HIV-1 IN catalyzes
the insertions of the resulting viral double strand DNA into the host genome [287].
The reaction is accomplished in two distinct steps, both mediated by a triad of
acidic residues in the ”Asp-Asp-(35)Glu” motif (two aspartates and a 35 amino acids
distant glutamate) present across all retroviral INs [93, 288, 289, 290, 291, 292]. 1.
In the first step of integration, HIV-1 IN removes the two terminal nucleotides
(GT) from 3’-ends of the double-stranded viral DNA and in the second step, called
’strand transfer’ or ’joining’, HIV-1 IN mediates the nucleophilic attack of the free
3’-hydroxyl groups of the viral DNA on the target chromosomal DNA, resulting in
the covalent joining of the two molecules [293].
Several cellular and viral interactors of HIV-1 IN are necessary for DNA integration
[294]. These include HIV-1 RT and a number of host proteins, such as human
(h)LEDGF/p75, hp300, hINI1, hVBP1, hPin1 and others [295, 296, 297, 298, 299].
The importance of these interactions is supported by the findings that some HIV-1
IN mutants, despite the fact that their purified HIV-1 INs display wild type levels
of catalytic activity, are unable to replicate properly [300, 301, 302, 303]. This can
be due, among other reasons, to the disruption of crucial interactions between viral
proteins and cellular partners [34, 36, 37].
Some of us have described the phosphorylation-dependent interaction of HIV-1 IN
with human prolyl-isomerase-1 (hPin1) [31]. Such interaction increases the stabil-
ity of HIV-1 IN and is a requisite for efficient HIV-1 integration and infection [31].
hPin1 facilitates conformational changes of its substrates by catalyzing the cis/trans
isomerization of the peptidyl-prolyl bond. hPin1 recognizes and isomerizes specif-
ically phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs [304]. Its action has an
important impact on cell proliferation immune response, neuronal differentiation and
in several diseases including neurodegenerative diseases and cancer [305, 306, 307].
In an effort to provide insights into the molecular basis of such interaction, we present
here a structural prediction of the complex between HIV-1 IN and hPin1. The
prediction is based on structural information available for the two isolated proteins.
The structure of hPin1 is available from NMR spectroscopy [308, 309]. It consists
of two domains [32, 33]: a small amino-terminal domain (’WW’, amino acids 1-
39) that binds specifically to pSer/Thr-Pro motifs and a carboxy-terminal peptidyl
prolyl-isomerase domain (’PPIase’, amino acids 45-163) that catalyzes the cis-trans
isomerization of the pSer/Thr-Pro bonds. The two domains are connected by a short
flexible linker region [310].
1Among the 276 known IN sequences (PROSITE profile PDOC50994) Asp,Asp(35)Glu motif
are conserved with 96%, 97%, 97% identity, respectively. [93, 288, 289, 290, 291, 292]
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HIV-1 IN exists as a homotetramer in vivo when associated with LEDGF/p75 pro-
tein [116] and possibly when it is bound to the DNA, as observed in a related IN
of a prototypic foamyvirus (PFV) [29]. HIV-1 IN’s multimeric state in any other
phase of the virus’ cell life is currently unknown [115]. The enzyme is present as a
monomer, homodimer, and homotetramer in vitro [29, 112, 117, 118, 119, 120, 121,
104, 311, 312]. The structures of the monomer, dimer, and higher order multimers
have not been characterized yet. So far, it is known that the monomer (288 amino
acid, monIN hereafter) consists of three domains [313, 297]: an N-terminal domain
(NTD), a catalytic core domain (CCD) and a C-terminal domain (CTD). The NTD
roles in 3’ processing and strand transfer [314], while CTD binds DNA nonspecifically
and has some roles in 3’ processing and strand transfer [314]. The CCD contains
the active site responsible for catalyzing the reactions of integration/dis integration
[313, 314, 315, 316]. The structures of the individual domains and of two distinct two-
domain fragments have been determined along with the structure of the monomeric
unit in complex with LEDGF/p75 [29, 123, 124, 293, 317, 318, 319, 320, 321, 322].
The three domains are connected by flexible linkers [115]. HIV-1 monIN’s full-length
structure was predicted in this work either by taking advantage of the overlapping
region between the NTD-CCD [123] and CCD-CTD [124] fragments, or by homology
modeling using as templates the orthologous enzyme from the PFV in complex with
a 19-base-pair oligomer (PFV IN•DNA) [29], the NTD-CCD [123], and the CCD-
CTD [124]. It is worth noting that, albeit showing only 33% of sequence identity,
PFV IN and HIV-1 IN likely share the overall tertiary structure [103].
Since neither the stoichiometry of HIV-1 monIN•hPin1 complex nor the sequence of
events involved its formation are known, we have used a relatively simple approach:
we separately modeled the HIV-1 monIN•hPin1-WW and HIV-1 monIN•hPin1-
PPIase complexes. The hPin1-WW and hPin1-PPIase domains are then docked onto
the two HIV-1 monIN models using the HADDOCK program [264, 17], by exploiting
the following information: (i) isomerization occurs upon cellular c-Jun N-terminal
kinase (JNK) mediated phosphorylation of HIV-1 IN on a highly conserved serine
(Ser57-Pro58) residing in the core domain [31]; (ii) hPin1(Y23A) mutant, which
bears a Y to A substitution in the hPin1-WW domain, is incapable of binding HIV-1
IN [31]; and (iii) HIV-1 IN is still capable of binding mutant hPin1(C113A), in which
target binding is preserved, while catalytic activity is abolished [31]. The models,
validated against side mutagenesis experiments performed in this work, have lead
us to suggest that mutations known to cause resistance on the viral protein surface
(the so-called ”Class II mutants” [323]) may affect this interaction.
4.2 Results
4.2.1 Structural Predictions
We predicted the HIV-1 monIN structure either by superimposing the CCD domain
of the HIV-1 IN NTD-CCD X-ray structure [123] onto the HIV-1 CCD-CTD X-ray
structure [124] (model A) or by homology modeling based on the PFV IN X-ray
structure [29] and HIV-1 IN NTD-CCD, CCD-CTD domains [124, 123] (model B).
The values of the root mean square deviations of the backbone without hydrogen
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atoms (RMSDb hereafter) of A and B are 1 A˚, 1.8 A˚, 4.8 A˚ for NTD, CCD and
CTD, respectively (see SI, Figure 4.7). The CTD domain in the two models differs
mostly for the orientation of the loop 229-239 (see SI, Figure 4.7). The Asp-Asp-
(35)Glu motif triad is instead structurally similar in the two models (see SI, Table
4.2). In both cases, HIV-1 monIN domains are organized in an extended manner
(see Figure 4.1 A and Figure 4.2 A). These resemble the way that they are disposed
in the PFV IN•DNA complex X-ray structure [29]. However, in the latter the two
interdomains linkers interact with each other (SI, Figure 4.8), whereas they do not
in the HIV-1 monIN models A and B (Figure 4.3). This is due, at least in part, to
the shorter length of the linkers in HIV-1 monIN relative to that of PFV IN (16 or
10 amino acids for linker 1 or 2 in HIV-1 monIN models and 10 or 50 amino acids for
corresponding linkers in PFV IN, respectively). The resulting docking models for
HIV-1 monIN•hPin1-WW (Figure 4.1 for model A and Figure 4.2 for model B) do
not rearrange significantly. Indeed, (i) the RMSDb relative to the unbound states
are 2.3 A˚ and 1.0 A˚ for the complexes based on models A and B, respectively (to
avoid ambiguities hereafter we will refer to model B using the italic typeface); and
(ii) the contact surfaces between the two proteins turn out to be structurally and
electrostatically complementary in both models A and B. This finding is consistent
with the proposed role of hPin1-WW as responsible for the molecular recognition of
the sole pThr/Ser-Pro motif of hPin1 substrates [324].
The buried surfaces are ∼250 nm2 and ∼253 nm2 for HIV-1 monIN•hPin1-WW
complex models A and B, respectively. The values for the HIV-1 monIN models and
hPin1-WW in models A / B, are ∼160/∼166 nm2 and ∼94/∼94 nm2, respectively.
Of these, ∼32% and ∼39 % pertain to hydrophobic residues, mostly in the HIV-1
monIN CTD regions (SI, Table 4.3). The overall buried surface is mostly hydrophilic
with intermolecular hydrogen bonds (H-bond) and salt bridges. An important role
for these interactions is played by IN-Asp207 and IN-Lys136 (Figure 4.4). Indeed,
the first forms a salt bridge with hPin1-Arg14 in model A and hPin1-Arg17 in
model B. The latter forms an H-bond to hPin1-Ser19 in model A and a salt bridge
with hPin1-Glu35 in model B. There, the alkyl moiety of the lysine side chain also
forms a hydrophobic interaction with hPin1-Trp34’s ring (Figure 4.4). IN-Lys136
has been already shown to be crucial in determining the affinity of hPin1-WW to
other targets. Its mutation to Ala destroys the interaction between hPin1 and its
substrate [325].
In contrast to hPin1-WW, binding to hPin1-PPIase determines a rearrangement
of the relative positions of HIV-1 monIN domains (see Figure 4.1 and Figure 4.2)
relative to the unbound state: the RMSDb’s are ∼18.0 A˚ and ∼16.5 A˚ for HIV-1
monIN in model A and B respectively; moreover, the centers of mass of the NTD
and CTD domains are displaced by ∼16 and ∼27 A˚ for model A, and ∼20 and ∼15
A˚ for model B, respectively.
The moieties undergoing the largest rearrangements are the two flexible linkers from
IN-Lys46 to IN-Trp61 and from IN-Gly134 to IN-Tyr143 in model A, and IN-Lys186
to IN-Ser195 in model B. Furthermore intra-domain rearrangements involve the C-
term alpha helix (from IN-Ser195 to IN-Ala205 and IN-Ala205 to IN-Lys219 in
models A and B, respectively). The helix rotates by about 500 in model A and it
is displaced by 83 0 in model B. Finally, the contact surface is slightly smaller than
that in the HIV-1 monIN•hPin1-WW complex: ∼210/∼206 nm2 to be confronted to
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Figure 4.1 Structural determinants of the complex HIV-1 monIN•hPin1
model A. (A-B) Molecular surface of HIV-1 monIN (A), and the two hPin1 do-
mains (B). Negatively charged, positively charged, polar and neutral residues are
colored in red, blue, green, white, respectively. (C) Comparison of HIV-1 monIN in
the isolated state (blue) and docked to hPin1-WW (left) or to hPin1-PPIase (right).
Only alpha-carbon is shown. (D) Molecular surfaces of the HIV-1 monIN•hPin1-
WW and HIV-1 monIN•hPin1-PPIase docked structures. Coloring scheme as in
(A-B).
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Figure 4.2 Structural determinants of the complex HIV-1 monIN•hPin1
model B. (A-B) Molecular surface of HIV-1 monIN (A), and the two hPin1 do-
mains (B). Negatively charged, positively charged, polar and neutral residues are
colored in red, blue, green, white, respectively. (C) Comparison of HIV-1 monIN in
the isolated state (blue) and docked to hPin1-WW (left) or to hPin1-PPIase (right).
Only alpha-carbon is shown. (D) Molecular surfaces of the HIV-1 monIN•hPin1-
WW and HIV-1 monIN•hPin1-PPIase docked structures. Coloring scheme as in
(A-B).
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Figure 4.3 Architecture of full length HIV-1 monIN, model A and B with NTD
(yellow), CCD (red), CTD (yellow) domains and linkers indicated (green).
∼16/∼16 nm2 for HIV-1 monIN in models A/B and ∼56/∼62 nm2 hPin1-PPIase
in models A and B, respectively.
The shape and electrostatic complementarity between HIV-1 monIN and hPin1-
PPIase is greater than the corresponding ones in the HIV-1 monIN•hPin1-WW
complex ((Figure 4.1)A,B,D and (Figure 4.2)A,B,D for unbound and bound condi-
tions) in both models. The overall buried surface is mostly hydrophilic (∼60% and
66 % for models A and B).
Sixteen salt bridges between HIV-1 monIN and hPin1-PPIase are formed in both
the models (SI, Table 4.4). In model A, two integrase residues involved in salt
bridges in the HIV-1 monIN•hPin1-WW complex (IN-Lys136 and IN-Asp207) also
form salt bridges with hPin1-PPIase-Glu76 and hPin1-PPIase-Arg56, respectively
(Figure 4.4). In model B, IN-Lys136 forms a salt bridge with hPin1-Glu76 as in
model A, while IN-Asp207 makes a salt bridge with hPin1-Arg54 and hPin1-Arg56.
Other details of the interactions are reported in the SI.
4.2.2 Biochemical validation of the structural predictions
In light of the computational results described above, we conclude that two residues
of HIV-1 IN form significant interactions with both hPin1-WW and hPin1-PPIase,
IN-Lys136 and IN-Asp207. Aimed at verifying experimentally this theoretical pre-
diction, we used Flag-tagged HIV-1 IN mutants at these two residues and tested the
binding to recombinant hPin1 by GST-pulldown experiments. Lysates from cells
transfected with wild type HIV-1 IN or the two mutants were incubated with GST-
hPin1 beads and the amount of retained protein was evaluated by western blotting.
As shown in (Figure 4.5)., binding to the IN-Lys136 and IN-Asp207 mutants was
significantly impaired compared to the wt protein (<75% and <25% respectively).
The gel at the bottom of (Figure 4.5). shows that both wt HIV-1 IN and the two mu-
tants were expressed at comparable levels inside the cells. Both IN-Lys136Glu and
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Figure 4.4 Structural determinants of the complex HIV-1 monIN•hPin1 model
A and B with the contacts of HIV-1 IN-Lys136 and IN-Asp207 (A-B) HIV-1
monIN•hPin1-PPIase complex and the contacts of HIV-1 IN-Lys136 and HIV-1 IN-
Asp207 with hPin1-Glu76, hPin1-Arg56 in model A (A) and hPin1-Glu76, hPin1-
Arg54/Arg56 in model B (B) . (C-D) HIV-1 monIN•hPin1-WW complex and the
contacts of HIV-1 IN-Lys136 and HIV-1 IN-Asp207 with hPin1-Glu35/Trp34, hPin1-
Arg14 in model A (C) and hPin1-Ser19 and hPin1-Arg17 in model B (D) . The pro-
teins are shown in trace (C alpha only), hPin1 is colored in iceblue, HIV-1 monIN is
colored in red and green for CCD and NTD/CTD, respectively. The contact residues
are shown in sticks.
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IN-Asp207Lys mutants are still phosphorylated (data not shown). So the reduced
interaction of these mutants may be caused by the reduced interaction of IN-Lys136
and IN-Asp207 with hPin1 residues.
Figure 4.5 Binding assay of the mutants predicted from the model. Lysates
of HEK 293T cells transfected with IN-flag or IN-flag or IN-flag where subjected to
GST and GST-hPin1 pull-down, followed by a Western Blot with anti-flag antibody.
The histogram in the upper part of the panel quantifies the relative amount of bound
HIV-1 monIN for each of the two mutants (WT=100%).
4.3 Discussion and Conclusions
Mounting evidence obtained over the last few years clearly indicates that HIV-1
infection relies on the interaction of viral proteins with a number of cellular partners.
These may either act by favoring various steps of the viral replication cycle, or,
conversely, by restricting replication in specific cell types or under physiological
circumstances [326]. Understanding the modes of interaction between viral and
cellular proteins is of obvious interest in light of the possibility of identifying surface
contacts amenable to novel drug development [327]. HIV-1 IN interacts with several
cellular proteins, which crucially affect various aspects of its activity [297]. Recent
X-ray experiments have improved our understanding of the PFV IN dimer-dimer and
DNA interaction, the so-called intasome [29]. However, structural characterization
of host-IN interaction is only available for the HIV-1 IN-LEDGF/p75 complex, based
on NMR and X-ray experiments [29, 317, 318, 319].
We have recently observed that one of the crucial partners of HIV-1 IN is the cel-
lular prolyl-isomerase hPin1 [31]. This enzyme binds HIV-1 IN, phosphorylated at
Ser57 by the JNK MAPK, and catalyzes a conformational modification resulting in
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increased protein stability without significantly affecting enzymatic function. Lack
of HIV-1 IN phopshorylation by JNK and the consequent lack of hPin1-mediated
HIV-1 IN isomerization restricts HIV-1 infection in resting T cell. Of course, hPin1
might bind HIV-1 IN before the isomerization takes place. Thus, determining the
structural characteristics of HIV-1 phospho- IN•hPin1 interaction is of great interest
in light of the possibility for developing novel therapeutics.
Towards the characterization of HIV-1 IN•hPin1 interactions, a major uncertainty
is that neither the oligomeric state of HIV-1 IN in the HIV-1 IN•hPin1 complexes
nor the sequence of events leading to HIV-1 IN binding to hPin1 are known. In par-
ticular, it is unclear whether the two hPin1 moieties (hPin1-WW and hPin1-PPIase)
simultaneously bind to a HIV-1 IN multimeric structure or, conversely, bind the same
monomeric structure at different times. Therefore, in this work we have adopted the
simplest possible approach by separately modeling the HIV-1 IN monomer with ei-
ther hPin1-WW and / or hPin1-PPIase. An additional potential limitation of our
modeling work is the uncertainty regarding the presence and location of metal ions
and the potential influence that DNA and/or other cellular partners might exert on
the HIV-1 IN•hPin1 complex.
Given these caveats, our HIV-1 monIN•hPin1 models, based either on HIV-1 monIN
domains or full length PFV IN, predict the formation of important contacts involving
IN-Lys136 and IN-Asp207. The mutation of these residues performed here effectively
abolished experimental interaction between HIV-1 monIN and hPin1-WW. These
results support the validity of our models.
Our models suggest that the proposed monomer structure of HIV-1 IN undergoes a
structural reorganization upon binding to hPin1-PPIase, which leaves the catalytic
core unaffected but causes a rearrangement in the reciprocal configuration of the
protein domains. This result is consistent with the observation that, upon incubation
of HIV-1 IN with hPin1, no detectable modification of HIV-1 IN catalytic function
could be observed. However the structure of protein was significantly modified, as
detected directly by susceptibility to subtilisin protease digestion and indirectly by
susceptibility to proteasome modification [31].
Interestingly both the unbound and the HIV-1 monIN bound hPin1-WW conforma-
tions have subunit architecture. In contrast, the structure of HIV-1 monIN changes
upon binding to hPin1-PPIase. This structural modification highlights the impor-
tance of considering protein interaction partners when discussing protein structure.
Molecular basis for Class II mutations and polymorphisms of HIV-
1 IN
The so-called ’Class II’ mutations impair protein function and HIV-1 virus replica-
tion in vivo without significantly affecting enzymatic activity [34, 35, 36, 37]. They
are pleiotropic, as additional defects at the post-integration and/or pre-integration
step of reverse transcription [323]. 2 Class II mutants involve the change of charge
(from positive to neutral, or from negative to positive, or from charge to neutral)
2This is in contrast with class I mutants, typically in the HIV-1 IN active sites, which are
blocked at integration step.
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of a variety of residues. These include HIV-1 IN-Lys34, -Asp55, -Arg199, -Lys211,
-Lys215 and -Lys219 [36, 37, 35, 328, 329] (See Table 4.1 and SI, Table 4.3, Table 4.4,
Table 4.5, Table 4.6). All of them interact with hPin residues in one or both of the
models predicted here Table 4.1. In addition, the mutation HIV-1 IN-Glu138Lys is
identified as a baseline polymorphism and displayed a high-level resistance to ralte-
gravir [330]. Also HIV-1 IN-Gly138 is located on the protein surface, and it interacts
with hPin in our models with IN-Arg69 in both models.
Table 4.1 Residues of HIV-1 monIN involved in Class II mutations and forming
contacts with hPin1 in our model(s).
Based on our modeling, we propose that some of these mutations decrease the sta-
bility of the complex between the viral integrase and hPin1, and hence affect HIV-1
IN overall stability, which depend upon such interactions [31]. This would be fully
consistent with the fact that the mutations affect viral replication and not enzymatic
activity [34, 35, 36, 37].
4.4 Methods
4.4.1 Structural predictions HIV-1 monIN
Experimental information is available neither on the full length HIV-1 monIN nor
on the oligomeric species of HIV-1 IN able to bind hPin1. Here we build the sim-
plest model, i.e. the monomeric one, in two ways. The first model (A) is based
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on two X-ray structures sharing overlapping regions: (i) the NTD/CCD fragment
[123] (PDBID 1K6Y) and (ii) the CCD/CTD fragment [124] (PDBID 1EX4). The
spatial arrangement of the three domains HIV-1 monIN was inferred from the over-
lapping region between the two structures. To this end the two core-domains were
superimposed and the three-domain structural model was obtained by taking the
atomic coordinates of residues from IN-Phe1 to IN-Lys186 from the PDB entry
1K6Y and of residues from IN-Arg187 to IN-Asp270 from the PDB entry 1EX4.
Two loops (from IN-Gly47 to IN-Asp55 and from IN-Gly140 to IN-Gln148) were
modeled using the Modeller8v program [23, 22, 331, 332] by generating a set of 3000
loop conformations, refining the loops using the DOPE scoring function [333], and
taking the most representative loop conformation. The latter was found adopting
the clustering protocol described in Ref. [334] with a nearest neighbor cutoff of 0.5
A˚. The most representative conformation was extracted from the most populated
cluster by choosing the structure with the minimum average RMSDb with respect
to all the other cluster members.
The second model (B), was built by homology modeling based on the PFV IN•DNA
complex X-ray structure [29] taking into account structural determinants from both
IN intasome from PFV PDBID 3L2R [29] and HIV-1 IN domains PDBID 1EX4,
1K6Y [124, 123]. The protocol used for the construction of this structural model of
HIV-1 monIN was follows: (i) Identification of appropriate templates: 5 iterations
of PSI-BLAST [212] of the target sequence HIV-1 monIN and the template PFV
IN sequence were run on BLAST server [209]. 250 sequences for each data set
were merged and clustered by CD-Hit server [335, 336, 337] into seven clusters
using a cutoff of 70% identity. The target was grouped into the most populated
cluster. The representative sequences of the next populated clusters were chosen,
including: HIV-1 monIN (target), full length PFV IN (PDBID 3L2R [29]), HIV-1
IN catalytic core and C-terminal domains structure (PDBID 1EX4 [124]), HIV-
1 IN N-terminal and core domains structure (PDBID 1K6Y [123]). (ii) Multiple
Sequence alignment: by ClustalW [338], MUSCLE [204], T-COFFEE [200] and PSI-
Coffee for distantly related proteins using homology extension algorithms [201, 202].
The results have been merged manually using JalView [339, 340] (SI, Figure 4.9).
(iii) Homology Modeling and Evaluation: The 3D models of HIV-1 monIN were
produced by Modeller9.9 program [23, 22, 331, 332] by generating a set of 3000
models. Loop refinement by Modeller9.9 [22, 331, 332, 23] was performed for residue
ranges 47-58, 229-239. The best-scoring models ranked on DOPE [333], molpdf
[23, 22, 331, 332] and GA341 [341] scores were selected. These models provided
also the best stereochemistry, as monitored by ProcheckV3.5 [342] programs and
Ramachandran plot [238]. (iv) Side-chain conformations prediction of the selected
models: using SCWRL4.0 [230].
4.4.2 Structural determinant of HIV-1 monIN•hPin1 complex
Human hPin1. The structure of the full length hPin1 in the free state has been
solved by NMR [308]; model 1, which possesses the lowest RMSDb between the 10
models reported in the PDB entry 1NMV [308], was used.
HIV-1 monIN•hPin1 complex. The two domains of hPin1 (hPin1-WW and
hPin1-PPIase) were docked onto HIV-1 monIN separately using the HADDOCK
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program [264, 17]. We used only one subunit of hPin1 at the time, without linker.
This procedure is not expected to greatly affect the results, because the linker and
the subunit hPin1-WW should not be involved in the interaction with HIV-1 monIN
when subunit hPin1-PPIase is bound to HIV-1 monIN. The experimental informa-
tion obtained from hPin1-mutants binding assays along with that extracted from
the structures of hPin1-WW and of hPin1-PPIase in complex with phosphorylated
peptides [130, 343] were used to define ambiguous distance restraints.
For hPin1-WW, residue-residue contacts involving phosporylated-Ser and Pro residues
were extracted from the only two NMR structures available of complexes between
hPin1-WW and phosphorylated peptides. These are the GluGlnProLeu-pThrProValThrAspLeu
(from the target Cdc25) and the LysVal-pSerValValArg-pThrProProLysSerProSer
(from the target tau) peptides (PDBID 1I8G and 1I8H, respectively [343]). The
crucial role in HIV-1 IN binding of Tyr23 emerged from the binding assays [31], was
also taken into account. This information was used to define ambiguous restraints
between these two sets of amino acids: (i) pSer57 and Pro58 from HIV-1 monIN
and (ii) Ser16, Arg17 and Tyr23 from hPin1 (Figure 4.6).
For hPin1-PPIase, we used the only structure of the hPin1-PPIase domain bound
to a L-peptide, the Phe-pThr-2-carboxypiperidine-β-(2-naphthyl)-Ala-Gln ligand
(PDBID: 2ITI [130]. The contacts involving the phosphorylated Ser and Pro (pSer
and pPro) residues are used to define ambiguous restraints between these two sets
of amino acids: (i) pSer57 and Pro58 from HIV-1 monIN and (ii) Ser58, Phe134,
His157 from hPin1-PPIase (Figure 4.6).
Figure 4.6 Distance restraints used in A) HIV-1 monIN•hPin1-WW and B)
HIV-1 monIN•hPin1-PPIase docking. hPin1 and HIV-1 monIN starting models are
depicted in white sticks. The carbon atoms of the residues involved in restraints are
represented as red spheres. Distance restraints are drawn as yellow sticks.
Each HADDOCK docking procedure consisted of the following steps: (i) generation
of 1,000 randomized starting configurations. For each configuration a rigid body
energy minimization is performed; (ii) semi-rigid simulated annealing in torsion
angle space performed on the 200 top-ranking conformations obtained in i); and
(iii) final refinement of the conformations resulting from the stage ii) in Cartesian
space with explicit solvent. The top ranking docked conformation of the top ranked
cluster was then retained.
Docking the pSer-Pro recognition motif of HIV-1 monIN models A and B onto
hPin1-WW was straightforward. The cleft surrounding such motif is structurally
and electrostatically complementary to the hPin1-WW recognition site. In contrast,
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for both models A and B, straightforward docking of this motif onto hPin1-PPIase
was not possible because of steric hindrances. It required a significant rearrangement
of the two linker regions connecting the three HIV-1 monIN domains. For model A,
we first docked hPin1-PPIase on a fragment of HIV-1 monIN which does not include
the NTD and the CTD (it includes the CCD and both the linker regions). Then,
the NTD and CTD were manually added and the resulting complex was refined with
the HADDOCK program [264, 17] by performing a simulated annealing MD run in
which only the backbone angles of the two flexible linkers regions were allowed to
move. For model B, the CCD of HIV-1 monIN was docked to hPin1-PPIase. hPin1-
PPIase domain bound to D-peptide (Ac-Phe1-l-P.Thr2-Pip3-Nal4(naphthylalanine)-
Gln5-NH2), PDBID 2Q5A [130] was used as initial conformation of hPin1-PPIase.
The contacts involving the pSer and pPro residues have been used to define am-
biguous restraints between these two sets of amino acids: (i) pSer57 and Pro58
from HIV-1 monIN and (ii) Lys63, Arg69, Ser154, Leu122, His59, Met130, Phe134,
and His157 from hPin1-PPIase [304, 130, 344]. The representative structure from
the most populated cluster retains all of the contacts found in the X-ray structure,
PDBID 2Q5A [130] (SI, Figure 4.10 and Table 4.5). The CTD and NTD were added
to the core domain of monIN (in complex with hPin1-PPIase) using homology mod-
eling. The HIV-1 monIN•hPin1-PPIase model was refined using docking. The same
ambiguous restraints used in the first docking step were reused. The hPin1-PPIase
and the core domain of HIV-1 monIN were constrained to be rigid, while the linkers
and the NTD and CTD of HIV-1 monIN were left fully flexible.
4.4.3 In vitro binding assays and immunoprecipitation
The pFlag-IN mutated in IN-Lys136 and in IN-Asp207 was constructed using re-
combinant PCR starting from the original vector. Codon-optimized pFlag-IN was
kindly provided by Dr. A. Engelman.
GST pull down assays with recombinant hPin1 were performed as previously de-
scribed [29]. Briefly, HEK 293T cells, transfected with pFlag-INwt, pFlag-INK136E
and pFlag-IND207K, were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 10% glycerol, 0.5% NP-40, 100 mM NaF 1 mM sodium orthovanadate
and Protease inhibitor cocktail EDTA free (Roche) and incubated with recombinants
GST-hPin1 proteins for 1 hour at 40C. Proteins were resolved by SDS-PAGE elec-
trophoresis and revealed by Western Blot using an anti-Flag antibody (Stratagene).
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Figure 4.7 HIV-1 monIN: the structures of its domains (CCD, NTD and CTD)
of models A (white) and B (violet) are superimposed.
Figure 4.8 Architecture of full length PFV IN [4] with NTD (yellow), CCD
(red), CTD (cyan) domains and linkers indicated (green).
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Table 4.2 Calculated root mean square deviations of the backbone non
hydrogen atoms (RMSDb) values between full length HIV-1 monIN model A
and model B (in italic) and the templates: PFV IN (PDBID 3L2R [4]), HIV-1
CTD-CCD fragment (PDBID 1EX4 [284]), HIV-1 CCD-NTD fragment (PDBID
1K6Y [285]).
Table 4.3 Reported salt bridges (SBs) in HIV-1 monIN•hPin1-WW com-
plex, model A and B
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Figure 4.9 Multiple sequence alignment between HIV-1 IN and the struc-
tural templates used here, these are PFV IN•DNA complex X-ray structure
PDBID 3L2R [4] and HIV-1 IN domains, PDBID 1EX4, 1K6Y [284, 285]. The se-
quences are colored follow the Clustal scheme colour [161]. The figure was generated
using JalView [163].
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Figure 4.10 The HIV-1 monIN-CCD•hPin1-PPIase model B (olive) is
superimposed to the correspondent one as obtained by X-ray, PDBID
2Q5A (cyan) [162]. IN-pSer57 and IN-Pro58 are shown in sticks.
Table 4.4 Reported salt bridges (SBs) in HIV-1 monIN•hPin1-PPIase
complex, model A and B
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Table 4.5 Residues in contact between hPin1-PPIase and monIN-CCD by
experimental data [162] used as ambiguous distance restraints in docking of HIV-1
monIN-CCD•hPin1-PPIase model B
Table 4.6 Reported salt bridges (SBs) in HIV-1 monIN•hPin1-WW complex,
model A and B
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5
HIV-1 Tat Binding to PCAF
Bromodomain: Structural
Determinants from Computational
Methods
Abstract
The binding between the HIV-1 trans-activator of transcription (Tat) and p300/
(CREB-binding protein)-associated factor (PCAF) bromodomain is a crucial step in
the HIV-1 life cycle. However, the structure of the full length acetylated Tat bound
to PCAF has not been yet determined experimentally. Acetylation of Tat residues
can play a critical role in enhancing HIV-1 transcriptional activation. Here, we have
combined a fully flexible protein-protein docking approach with molecular dynamics
simulations to predict the structural determinants of the complex for the common
HIV-1BRU variant. This model reproduces all the crucial contacts between the Tat
peptide 46SYGR(AcK)KRRQRC56 and the PCAF bromodomain previously reported
by NMR spectroscopy. Additionally, inclusion of the entire Tat protein results in
additional contact points at the protein-protein interface. The model is consistent
with the available experimental data reported and adds novel information to our
previous structural predictions of the PCAF bromodomain in complex with the rare
HIVZ2 variant, which was obtained with a less accurate computational method. This
improved characterization of Tat•PCAF bromodomain binding may help in defining
the structural determinants of other protein interactions involving lysine acetylation.
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5.1 Introduction
The development of drugs against human immunodeficiency virus type 1 (HIV-1)
was initiated about 30 years ago [345]. Since then, there have been 30 available
antiretroviral drugs approved by the U.S. Food and Drug Administration (FDA).
Current therapies against the AIDS pandemic are mainly based on inhibition of the
three enzymes expressed by HIV-1 (protease, reverse transcriptase and integrase)
[9, 52, 346, 347]. Unfortunately, all of these approaches suffer from drug resistance
due to the emergence of viral mutants [7]. In a rapid process of Darwinian evolution,
the virus has developed functional enzyme variants not inhibited by current thera-
pies/drugs. Several promising new strategies may, at least in part, counteract such
viral hypervariability [157, 158]. One of these strategies interferes with the HIV-1
transcriptional activity induced by the HIV-1 trans-activator of transcription (Tat)
protein [38, 39, 348] (Figure 5.1 A).
Tat is also acetylated at K28 by the p300/CBP-associated factor (PCAF), thereby
enhancing Tat binding to the protein P-TEFb [44]. This may in turn regulate func-
tionally critical steps in transcription [40, 41, 42, 43, 135, 131]. PCAF is a 90-kDa
protein that contains the P300/SRC-1 domain (residues 1 to 352), the HAT do-
main (residues 518 to 649), which acetylates K28 [40, 45] and a C-terminal BRD
(residues 719-832) [45]. The BRD (Figure 5.1 B) binds to the Tat protein, which is
acetylated at lysine 50 (AcK50). Despite the fact that the structural determinants
of full-length PCAF in complex with Tat have not yet been determined experi-
mentally, the NMR structure of the complex between an acetylated Tat peptide
(46SYGR(AcK)KRRQRC56) (Figure 5.1 C) and the PCAF BRD has been solved by
NMR spectroscopy [45].
The structural determinants of the full-length Tat•PCAF BRD complex were pre-
dicted based on molecular dynamics simulations, combined with biochemical and
FRET experiments [362]. This model was built using the structure of the isolated
Z2 variant of the HIV-1 Tat [363]. In contrast to the existing structures of BRDs
in complex with histone peptides, that model pointed to the presence of contacts
between the BRD and non-adjacent regions of the acetylated partner. Furthermore,
Tat Regions III and IV made extensive contacts with the ZA loop of the PCAF BRD
(Figure 5.1). Although these contacts were not present in the NMR structure, which
only contained a Tat peptide, they were experimentally validated [362], supporting
the idea that significant changes in the protein-protein interface may take place in
the presence of the entire Tat molecule.
Here we construct an updated structural model of the Tat PCAF BRD complex
using a more accurate docking procedure. This is the fully flexible protein-protein
technique as implemented in the data-driven docking program HADDOCK version
2.1 [17, 264] followed by molecular dynamics (MD) simulations. Importantly, we
focused on the 86 amino acids Tat BRU variant, PDBID 1JFW [349], a representative
of HIV-1 subtype B. This variant is actually the more common HIV subtype in
Europe and North America [364]. The Z2 variant of the protein used in our previous
study is evolutionally closer to early strains of the virus, but is nowadays much
less abundant [364]. Docking studies involving Tat and its cellular partners can be
expected to be feasible. Indeed, (i) HADDOCK (High Ambiguity Driven protein-
protein DOCKing) [17, 264] has been used to predict the protein-protein and protein-
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Figure 5.1 Molecular representation of Tat•PCAF model and interactions. (A)
HIV-1 Tat protein. The Tat protein lacks secondary structure elements[349]. Tat
consists of six regions: Region I (in red) includes a proline-rich tract. It plays
an important role in the entry of Tat into the cell [141]. Region II (in yellow)
includes a cystein-rich tract. It is important for the transactivation ability of Tat
[350]. Region III (in green) includes the motif RKGLGI. It is considered as the
hydrophobic core of the protein and is conserved across HIV-1, HIV-2, and SIV Tat
[351]. It does not have any known specific function [351]. Region IV (in orange)
contains the basic domain (49RKKRRQRR56), arginine-rich motif, conserved across
Tat proteins [352, 353]. This region is required for binding to the viral RNA TAR
(trans-activating response region) [354, 355, 356, 357, 358], as well as a variety of
proteins, including PCAF BRD [45]. Region V (in violet) is a glutamine-rich region
[359]. It is involved in microtubule polymerization and Tat-mediated apoptosis of
T-cells [359]. Region VI , (in blue, amino acid 73 to 86 or 101, depending on
the virus strain) [38, 39] includes the RGD motif that mediates Tat binding to
cell surface integrins [360]. It is involved in cell adhesion [361]; (B) PCAF BRD.
Cartoon representation of PCAF BRD NMR structure (PDBID 1JM4 [45]). It has a
four-helix bundle (helices αZ, αA, αB, and αC); (C) Tat’s core domain and arginine-
rich motif (ARM) interacting with PCAF BRD NMR structure [45]. PCAF BRD
(orange) is represented in cartoon and traced with the residues in contact with Tat
(green) in orange stick forms. Tat is represented in stick forms with oxygen and
nitrogen atoms of AcK50 in red and blue, respectively.
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nucleic acid complexes based on available experimental data [365, 366, 367]; (ii)
HADDOCK has also been applied to intrinsically disordered proteins for which NMR
structural information is available, such as Tat [40, 131, 362, 264]; (iii) HADDOCK
has been successfully applied to a variety of NMR structures with a low number of
NOE’s per atom [17, 365], similar to the ones we found in the available Tat NMR
structures. Moreover, HADDOCK complemented by MD also provides reasonable
results in those cases where the protein undergoes conformational changes [365, 366,
367]. Therefore by using the docking procedure combined with the MD simulations,
we believe that a reasonable model of Tat can be assured.
5.2 Results and Discussion
5.2.1 Intermolecular Contacts
In our full length Tat•PCAF BRD model, the interface between the BRU Tat and
PCAF BRD complex (BRU Tat•PCAF hereafter) consists of Tat residues 47-55
and PCAF BRD residues 722-781. We focus on the contacts at the protein/pro-
tein interface. We first describe the hydrophobic contacts (HCs). Then we move
our attention to intermolecular hydrogen bonds (HBs) and salt-bridges (SBs). The
residues belonging to PCAF BRD are indicated in the following text with italics,
while those of Tat with normal text.
AcK50 forms HCs with F748, V752, K753, Y760, I764, N798, Y802 and Y809 (Ta-
ble 5.1 and (Figure 5.2 A)). These results are in agreement with in vitro mutagenesis
experiments in which the mutants to alanine of these PCAF residues strongly dis-
missed the Tat•PCAF BRD binding [45]. The role of Y760 in binding has been
confirmed also in vivo by fluorescence resonance energy transfer (FRET) experi-
ments of full-length acetylated Tat with PCAF BRD [362]. The mutant Y760D
indeed impaired Tat binding to PCAF BRD (Table 5.1) [362]. Q54 establishes HCs
with PCAF E756. Both residues are located at the edge of a hydrophobic cavity of
Tat (Figure 5.2 B).
R49 forms HCs with P747, E750 ; K51 with E750, V752, K753 ; R52 with K753,
E756 (Figure 5.2A); and Y47 with P804, S807, E808 and Y809 (Figure 5.2B).
These results are also consistent with in vitro mutagenesis experiments [45]; alanine
substitution of residues R49, K51, R52, or R53 slightly weaken Tat’s binding to
the BRD [45]]. Similarly, the mutation of Y47 and Q54 to alanine hampers PCAF
BRD binding to the Tat46SYGR(AcK)KRRQRC56 peptide. Most of these HCs
are present in the Tat46SYGR(AcK)KRRQRC56•PCAF NMR structure [45] (Table
5.1). Additionally, our model predicts interactions between AcK50-K753, AcK50-
N798 (Figure 5.2 A ) and S46-Y809 (Figure 5.2 B ); the last predicted interaction
is possibly because residues flanking both sides of S46 contribute to the complex
formation (Figure 5.2 B). In addition, the V763 -Y47 contact is present in the NMR
structure only and absent in our model (Figure 5.2 C). This is due to the fact that
the formations of new HCs at the N-terminus affect the position of Y47 in the BRU
Tat•PCAF model. The new HCs include Tat E2 to PCAF E756, A757, P758 ; P3 to
P758 ; S46 to P804, Y809. As a result, the RMSD of Tat Y47 exhibits a difference
of 4.8 A˚ with respect to the full length Tat.
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Table 5.1 Effect of mutations in in vitro experiment for
Tat46SYGR(AcK)KRRQRC56 (synthesis) complex with p300/(CREB-binding
protein)-associated factor (PCAF) bromodomain (BRD) [45] or in vivo experiment
for full length acetylated Z2 Tat with PCAF BRD [362]. The corresponding contacts
in both BRU Tat•PCAF docking and molecular dynamics (MD) models presented
in this work are reported in the last columns (black=agreement; red=new contacts).
Coverage in the last column is the percentage of the occurrence of hydrophobic
contacts (HCs) over all frames in MD simulation.
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Figure 5.2 HIV-1BRU Tat•PCAF BRD interface (A) HCs between R49, AcK50,
R51 of BRU Tat (green) and PCAF BRD (orange) contacts at the core protein/pro-
tein interface are reported. Residues at the interaction interface are represented in
stick forms; (B) The HCs between BRU Tat (green) and PCAF BRD (orange) con-
tacts at the edge protein/protein interface are reported. Residues at the interaction
interface are represented in stick forms; (C) The position of Y47 (shown with balls)
and V763 (shown with sticks) represented in the complex of BRU Tat•PCAF model
were superimposed with the same residues in Tat46SYGR(AcK)KRRQRC56•PCAF
(black) NMR structure [45] (in green and orange, respectively); (D) A schematic
view of the HCs between BRU Tat and PCAF BRD. The red dotted lines are the
HCs newly found in BRU Tat•PCAF model; (E) The new HBs in BRU Tat•PCAF
model (in green and orange, respectively) with oxygen and nitrogen atoms in red
and blue, respectively; (F) salt-bridges (SBs) between BRU Tat (green) and PCAF
(orange) between R53-E756, R49-E750, K51-E750.
A schematic view of the HCs between Tat and PCAF BRD is shown in (Figure 5.2
D).
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Tat AcK50 forms HBs with V752, F748, N798, Y802 and Y809. Tat R53 and Tat
Q54 make HBs with PCAF E756 (Figure 5.2 E and Table 5.2). These HBs are also
present in the Tat46SYGR(AcK)KRRQRC56•PCAF NMR structure [45] (Figure 5.2
E) and are consistent with our model of Z2 Tat•PCAF [362].
New HBs between R49 and E750, P747 were found in our model (Table 5.2)at the
interface. In the N-terminal of Tat, E2 and P3 make a HB to PCAF P758.
Finally, the R53-E756, R49-E750, K51-E750 SBs are present (Figure 5.2 F) in the
BRU Tat•PCAF BRD model. These residues are all at the interface of Tat and
PCAF with the high density of basic/acidic residues. Only the first SB was present in
Tat46SYGR(AcK)KRRQRC56•PCAF NMR structure [45]. This SB was also present
in our previous model [362].
The five representative clusters of Tat•PCAF complex from MD simulation are com-
pared with the docked model and the NMR structure. The HCs are shown in
(Figure 5.1). The structures obtained by docking and those obtained by MD are
not too dissimilar (Table 5.1 and Table 5.2). In particular, some hydrophobic con-
tacts (AcK50-E756, AcK50-D769, Ack50-P747, R49-W746, R49-F748, R49-Y802,
K51-K753, K51-E756 ) are present in the MD structures but absent in the docked
structures. None of the intermolecular HBs with a coverage of more than 50% over
the frames is retained in MD. The models generated by data-driven docking and
MD show that the hydrophobic interactions may play a leading role in Tat•PCAF
BDB complex stabilization.
Table 5.2 Selected intermolecular hydrogen bonds (HBs) in the HIV-1BRU
Tat•PCAF model by docking.
5.2.2 Structural Rearrangements of Tat and PCAF upon Binding
In the Tat46SYGR(AcK)KRRQRC56•PCAF BRD complex [45], the binding inter-
face between Tat and PCAF BRD is composed of Tat residues 47-55 and PCAF BRD
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residues 722-781. The inclusion of the complete Tat protein in our model imposes
structural constraints that result in conformational differences, which, however, do
not significantly alter the identity of the contacts.
The structural changes mostly involve the Tat BRU variant: The RMSD of the back-
bone atoms between the Tat47YGRKKRRQR55 of our model and the NMR structure
of Tat46SYGR(AcK)KRRQRC56•PCAF BRD [45] is as large as 4 A˚. The RMSD of
the 47YGRKKRRQR55 segment relative to the Tat46SYGR(AcK)KRRQRC56•PCAF
BRD NMR complex [45] ranges from 2.6 A˚ to 3.4 A˚. A similar result is also found af-
ter MD simulations. Indeed, the binding regions (Tat47−55 and PCAF722−781 BRD)
rearrange 3.1 A˚ and 2.6 A˚, respectively, compared to the same residues on NMR
structures, while the whole complex shows remarkable changes (RMSD 24.5 A˚).
This indicates that the binding region rearranges less than the rest of the protein.
Dramatic changes were instead observed in the N-terminal segment on Tat upon
binding with the P-TEFb complex (see Supplementary Section S5.5 for more details
[44]).
Notably, the RMSD between the present model (using the BRU variant) with that
previously reported by us for the Z2 variant [363] (which has 79.1% sequence identity
with BRU Tat, (see Figure 5.3) is as much as 9.5 A˚. The main differences involve
the N-termini, with a RMSD of 17 A˚ dissimilarity between the two structures, and
the C-termini which differ by as much as 14 A˚; the Tat46SYGR(AcK)KRRQRC56 is
more conserved, with 3.3 A˚ dissimilarity. The AcK50 in BRU and Z2 Tat•PCAF
BRD model was outside the Tat loop such as K50 in Tat full-length BRU variant in
unbound conformers. In Z2 Tat full-length, the K50 instead turns inside the loop
(Figure 5.3 B). We further notice that in spite of their differences in sequence and
overall structure (Figure 5.3 B), the N-termini of Z2 and BRU Tat form similar
contacts with PCAF BRD and residues in the N-terminal extremity of Tat. Dif-
ferent segments for the Z2 and BRU variants of Tat are conserved in terms of the
intermolecular contacts with PCAF [364], as described in Section 5.2.1.
The PCAF BRD structure remains close to the protein in the free state in solution:
The RMSD of the backbone relative to that of the NMR structure [45] [45] is only
0.8 A˚ (Table 5.1).
We further notice that docking of the Tat46SYGR(AcK)KRRQRC56 peptide onto
the PCAF BRD (see Methods Section 5.4 and Supplementary Section S5.5) resulted
in structural deviations differing by 0.9 A˚ and 1.3 A˚ for each of the components and
1.7 A˚ for the whole complex (Table 5.3). These values are well within the range of
variation of RMSD reported for the NMR structure described in (Table 5.3). This
may suggest that our docking procedure is rather accurate.
5.2.3 Key Residues of PCAF BRD for Its Interaction with Tat
The sequence and structure conservation of Tat has been discussed by us in [364].
Here we focus on residues of PCAF human BRD important for Tat binding (See mul-
tiple sequence alignment of PCAF human BRD in Figure 5.4. There are 53 PCAF
human bromodomain (BRD) sequences as obtained from bromodomain PROSITE
family, accession number PS50014 [368, 369, 370]. We start our discussion by listing
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Table 5.3 Calculated backbone RMSD values between the BRU Tat•PCAF dock-
ing and MD models and the Tat46SYGR(AcK)KRRQRC56•PCAF NMR structure
(conformer 8 [45], see Methods for details). The abbreviations min., max., avg.,
sd. stand for minimum, maximum, average, standard deviation of RMSD values,
respectively.
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Figure 5.3 (A) Superposition of Tat Z2 variant structure (red, the lowest backbone
RMSD on residue 46 to 56 in model 3rd) with Tat BRU strain structure (green, model
8th); the Tat46SYGR(AcK)KRRQRC56 peptide is in cartoon and K50 is in sticks.
(B) Sequence alignment and degree of conservation between Z2 Tat and BRU Tat,
as obtained by the ClustalW [345] software. Color code as in [345].
the most conserved residues of this protein family (Table 5.4). In particular, P758,
which makes HBs with E2 and P3 of Tat, is highly conserved among PCAF BRD
sequences (71% identity, (Table 5.4) and P747 (identity 53% respect to PCAF BRD
sequences, Table 4 and Figure 5.4. Notably, the N798, which makes an HB with
AcK50, is one of the most conserved residues in PCAF BRD (96%, (Table 5.4).
P747 and N798 residues, which are involved in several HCs and HBs (Table 5.1)
and (Table 5.2) and Supplementary Tables 5.7 and 5.5), seem to play an important
role for the Tat•PCAF interaction. Moreover, due to the overall structure similar-
ities of PCAF BRD [371], the N798 may play an important role in the interaction
of PCAF BRD with other cellular partners [372].
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Figure 5.4 Multiple sequence alignment of the existing 53 PCAF human bromod-
omain (BRD) sequences as obtained from bromodomain PROSITE family, accession
number PS50014 [9, 347, 346]. The human PCAF BRD corresponding to the PDB
structure 1JM4 is the top sequence. Blue residues in the alignment denote residues
that have percentage of identity over 60 %. The figure was generated using JalView
[52].
5.3 Conclusions
We have presented a model of the BRU Tat•PCAF complex produced by data-driven
docking combined with MD simulations, which may add structural information to
the intricate mechanism of Tat transcription and trans-activation, up to now not
fully understood [38, 39]. The structures obtained by docking and those obtained
by MD are similar in the binding region. This model was obtained with a more
accurate procedure than that used in [362] and it focuses on the more common BRU
variant rather than the Z2 strain of HIV-1. The two models show conservation as
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Table 5.4 Conserved residues of the existing 53 PCAF human bromodomain (BRD)
sequences as obtained from the bromodomain PROSITE family, accession number
PS50014 [368, 369, 370].
far as the Tat46SYGR(AcK)KRRQRC56 and N-terminal contacts with PCAF BRD
are concerned. In addition, the model suggests the presence, only for the Z2 strain
of Tat, of hydrophobic contacts and hydrogen bonds between Tat and PCAF that
are not present in the previous model of Z2 Tat•PCAF [362]. Specifically, the BRU
Tat•PCAF model differs from the Z2 Tat•PCAF complex on HBs between R49 and
P747, E750, between P758 and E2, P3 and on HCs between S46 and P804, Y809.
The model appears to be consistent with most of the experimental data obtained
with Tat46SYGR(AcK)KRRQRC56•PCAF in vitro [45] (synthesized Tat peptide)
and full length Tat•PCAF in vivo [362]. However, this comparison has to be in-
terpreted with caution because of the assumption that most of the intermolecular
interactions compared here do not vary when passing from the in vitro to the in vivo
situation and/or from the Tat46SYGR(AcK)KRRQRC56 to the full length protein.
Several BRD amino acids have been identified as crucial for Tat binding (E750, V752,
E756, A757, Y802, Y809 ) and as the targets for development of small molecules
blocking Tat•PCAF association [171, 373]. Our model allows us to suggest that the
hydrophobic interactions seem to be a crucial factor for BRD binding to Tat.
Further, our model allows us to suggest that N798 in the BRD plays a key role
for Tat binding, independently of whether this protein is expressed by the BRU
or the ZZ variant of HIV-1. Indeed, this residue creates a HB with AcK50 in the
X-ray structure of Tat and other cellular partners [354, 355, 135], in both the Z2
Tat•PCAF model [362] and in our model. Hence, interfering with N798 -AcK50 in-
teractions may be a valuable strategy for drug design [372, 374]. Because this residue
is highly conserved (Supplementary Figure 5.4 and Table 5.4), it may form key in-
teractions also with other BRD cellular partners [45, 375, 376, 371, 377]. Moreover,
some studies showed that specific small molecules binding at the acetylated lysine
recognition pocket can antagonize the bromodomains and acetylate histone inter-
actions, especially the HB between asparagine in αB loop and acetylated lysine
[378, 374, 379, 380, 381, 382, 383, 384, 385, 386]. Therefore, designing compounds,
which bind to N798 may also lead to other potential therapeutic applications.
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The structure of HIV-1 Tat (86 residues) has been solved by NMR (PDBID 1JFW
[349]). Eleven conformers have been deposited. His13, His33, His65 are protonated
in the N [349]. We superimposed residues 47 to 55 in each of these structures with
the corresponding ones with the multiple conformers of Tat46SYGR(AcK)KRRQRC56
peptide in complex with human PCAF BRD, whose structure has been solved by
NMR. His717 and His742 were protonated in Nδ as in the NMR structure (1JM4
[45]). The VMD 1.8 program [387] was used. The conformer n.8 of HIV-1 Tat and
n.3 of the Tat46SYGR(AcK)KRRQRC56•PCAF complex exhibits the lowest pairwise
root-mean-square deviation (RMSD) in respect Tat46SYGR(AcK)KRRQRC56 back-
bone (2.3 A˚ and 0.7 A˚, respectively). All the RMSDs reported in this paper are cal-
culated using only backbone atoms. Thus, these conformers were selected for all sub-
sequent calculations. The full length Tat was fitted to Tat46SYGR(AcK)KRRQRC56
at the peptide then AcK50 was replaced with K50 in full length Tat using the tleap
module in AMBER package [388] with acetylated lysine parameters adapted from
Machado et al. [389]. The resulting structure was relaxed for 10 ns molecular dy-
namics simulation in water (See Supplementary Section S1; RMSF, RMSD of the
system plotted as a function of simulated time in Supplementary Figure 5.5 and
Figure 5.6 for further details). A clustering of the MD trajectory [390] identified
seven clusters, 84 structures in total, which represented 98% of the conformations
(Supplementary Section S2). These structures were docked on the 25 PCAF BRD
conformers present in the NMR family of structures (1JM4 [45]) by a multiple con-
formations docking procedure using the HADDOCK 2.1 program [17, 264]. Haddock
is an information-driven flexible docking approach for the modeling of biomolecu-
lar complexes [353]. The entire protocol consists of four stages: (i) Topology and
structure generation; (ii) Randomization of the starting orientation and rigid body
energy minimization; (iii) Semi-flexible simulated annealing; (iv) Flexible refinement
in explicit solvent (water).
We first validated our docking procedure by redocking the Tat46SYGR (AcK)KRRQRC56
from PCAF BRD in the NMR structure of the complex (Supplementary Section
S3) [45]. Then, the two binding partners were docked one onto the other by
rigid body docking with different Ambiguous Interaction Restraints (AIRs) (Sup-
plementary Section S5.5, Table 5.6, for the definition of AIRs, see [17]). The
adduct exhibited a backbone RMSD of 1.3 for PCAF BRD and 1.7 for HIV-
1 Tat46SYGR(AcK)KRRQRC56 with respect to the NMR structure (Supplemen-
tary Section S3, Figure 5.8 and Table 5.3). These results allow us to suggest that
HADDOCK performs well for this system (Supplementary Section S3). Next, we
performed rigid-body docking between PCAF BRD and Tat AcK50. The contacts
F748 -, V752 -, Y809 -, I764 -, Y760 -, Y802 - to AcK50, E756 - to R53, V763 - to Y47,
E756 - to Q54, present in the NMR structure, were treated as AIRs. The rigid-body
docking was followed by a rigid body energy minimization, a semi-flexible simulated
annealing in torsion angle space and a refinement by MD at a temperature of 300K
in explicit solvent [17, 391]. Next we selected the 500 top structures in terms of the
highest docking score and the lowest RMSD relative to the NMR structure [45]. In
these 500 structures, a short MD simulation was performed to optimize the water
positions while proteins were fixed (4,000 steps of MD consisting four times 1,000
steps at a temperature of 600, 500, 400 and 300 K, respectively [391]. This was
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followed by MD at 300K in water [17]. A clusterization procedure was performed
with a cut-off at 3.0 from the final 500 structures (94% structures were clusterized).
We finally selected the structure that had the lowest RMSD (0.8 for PCAF and 4
for Tat), which is representative for the most crowded cluster. This is the structure
discussed in the Results and Discussion Section. Other representative structures are
discussed in Supplementary Table 5.7.
The representative of the Tat•PCAF model from docking underwent MD simulations
in explicit water. Tat•PCAF BRD was solvated in 104 x 70 x 66 A˚3 box, containing
39.363 water molecules, 16 chlorine ions were added to neutralize the total charge of
the system. The AMBER force field ff99SB [392] was used for the protein and the
chlorine atoms; the TIP3P model [393] was used for water. The acetylated lysine
topology parameter was taken from Machado et al. [389].
Periodic boundary conditions were used and a cutoff of 12 A˚ [394] was adopted for
short-rangenon-bonded interactions. The particle mesh Ewald summation method
[395] was used for long-range electrostatic interactions. A dielectric constant of one
was assumed. All chemical bonds were constrained by using the SHAKE algorithm
[?]. The equations of motion were integrated using a time step of 2 fs. Temperature
and pressure were kept constant at 300 K and 1 atm by coupling the system to
external baths [271] with a Langevin thermostat (coupling constants st = 0.05) and
a Berendsen barostat (coupling constants sp = 0.5 ps), respectively.
After 5,000 steps of minimization (steepest descent algorithm for the first 1,500 steps
before switching to the conjugate gradient algorithm for the remaining 3,500 steps),
the system was equilibrated for 300 ps. Eighty nanoseconds of MD simulation were
performed at 300 K and 2 ps for the time steps. We clusterized [390] the trajectory
into five clusters. The backbone RMSD of the Tat•PCAF BRD structures over 80 ns
is shown in Supplementary Figure 5.6. NAMD package was used for MD simulation
[396].
Hydrophobic contacts at the protein/protein contact surface were defined as two non-
polar carbon atoms at a distance of 4.0 A˚ or less. Hydrogen bonds were defined as a
polar hydrogen at a distance of 2.5 A˚ or less from a polar atom (nitrogen or oxygen).
Salt bridges were considered formed if the distance between any of the oxygen atoms
of acidic residues and the nitrogen atoms of basic residues were less than 4.0 A˚.
Coverage was defined as the percentage of the occurrence of HCs over all frames in
MD simulation or all representative structures in docking. The HADDOCK [17, 264],
LIGPLOT [397] and VMD [387] programs were used to calculate these quantities.
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S1. MD simulation of AcK50-BRU Tatfull−length
The of AcK50-BRU Tatfull−length model was inserted in a simulation box of 0.12 nm
length containing ∼9,300 TIP3P water molecules [393] and 11 Cl– counterions for
neutralizing the system. Periodic boundary conditions were used and a cut-off at
12 A˚ [394] was adopted for short-range non bonded interactions. The particle mesh
Ewald summation method [395] was used for long-range electrostatic interactions.
A dielectric constant of 1 was assumed. All chemical bonds were constrained by
using the SHAKE algorithm [398]. The equations of motion were integrated using
a time step of 1fs. Temperature and pressure were kept constant at 300 K and
1 atm by coupling the system to external baths [271] with Langevin thermostat
(coupling constants st = 0.05) and Berendsen barostat (coupling constants sp = 0.5
ps), respectively. The AMBER force field ff99SB [392] was used. The acetylated
lysine topology parameter was adapted according to Machado et al. [389].
After 5000 steps of minimization (steepest descent algorithm for the first 1,500 steps
before switching to the conjugate gradient algorithm for the remaining 3,500 steps),
10 ns of MD simulation were performed (Figure 5.5). NAMD software [396] was
used.
We clusterized [390] the trajectory into 7 clusters (See Section S2). For each clus-
ter, 11 representative structures were selected (77 structures in total, grouped in
7 sets) for AcK50-BRU full-length Tat docking with PCAF BRD. They represent
98% of conformations (Figure 5.6). Finally, 7 representatives, having at least 3 A˚ of
backbone RMSD from each other, for a total ensemble of 77 structures were chosen.
Figure 5.5 RMSF of full length AcK50-Tat backbone at 5-6 ns (black); 9-10 ns
(red).
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Figure 5.6 MD simulation of full length AcK50-Tat in water: RMSD of the protein
plotted as a function of simulated time.
S2. Clusterization Procedure
AcK50-BRU Tatfull−length MD conformers were clusterized following the De Mori et
al. method [390]. We performed the clustering by different cut-offs (Table 5.5).
Cut-off 3.0 A˚ was chosen as described in Section 5.5.
Table 5.5 Performance of different cutoff in clustering MD conformers.
S3. Validation of docking parameters
Different Ambiguous Interaction Restraints (AIRs) were used to find the best pa-
rameters for docking (Table 5.6).
The conformer with the lowest RMSD of residues in the interaction interface (iRMSD)
respecting the NMR structure was chosen (Figure 5.7).
Our model reproduced almost all of the HCs present in the NMR structure [45].
The only hydrophobic contact not reproduced involved AcK50 in BRU Tat and
I764 in PCAF BRD. However, in the NMR structure, PCAF BRD I764 is a high
mobility residue [45], suggesting that this interaction might be not as strong as other
hydrophobic interactions at the protein/protein interface.
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Table 5.6 Ambiguous Interaction Restraints for docking BRU
Tat46SYGR(AcK)KRRQRC56 onto PCAF BRD.
Figure 5.7 Cartoon representatives in seven clusters of AcK50-BRU Tatfull−length,
residues 46-56 are shown in red and AcK50 in sticks.
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Figure 5.8 The structure of our predicted Tat46SYGR(AcK)KRRQRC56•PCAF
BRD complex is superimposed to that obtained by NMR [45]. AcK50 is shown in
sticks. The interface between the peptide and the protein is represented as a grid.
The van de Waals surface is represented in dots.
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S4. MD simulation of Tat.PCAF BRD complex
See Figure 5.9, Table 5.7, and Table 5.8
Figure 5.9 MD simulation of Tat.PCAF BRD in water: RMSD of the complex
plotted as a function of simulated time.
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Table 5.7 Hydrophobic contacts observed for the representative structures of clus-
ters 2, 3 and 4 from docked structures in comparison with in vitro experimental
works for Tat46SYGR(AcK)KRRQRC56 (synthesis) [45] or in vivo for full-length
acetylated Z2 Tat with PCAF BRD [362]. (black = agreement; red = new contacts).
The representative structure of cluster 1 is discussed in the main text. Coverage in
the last column is the percentage of the occurrence of HCs over the representative
structures.
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Table 5.8 Selected intermolecular HBs in the representative BRU Tat•PCAF mod-
els by docking. The residues with asterisk form new HBs. Coverage in the last
column is the percentage of the occurrence of HCs over the representative struc-
tures.
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S5. Tat in complex with cellular partners: the P-TEFb case
Structural information on full length HIV-1 Tat in complex with cellular partners
is not available. Complexes exist instead for Tat peptide [44, 45, 399, 400] with the
length ranges from 9 amino acids [400] to 49 amino acids [44] (Figure 5.10). HIV-
1 Tat peptide is always in an unfolded state [45, 399, 400], with exception of the
complex with P-TEFb, where HIV-1 Tat adopts an α helix [44]. The same docking
protocol discussed in the main text was successfully applied also for Tat•P-TEFb
complex (Figure 5.10 and Table 5.9). The best structure from the most populated
cluster after docking reproduced well most of the HCs and HBs comparing to X-ray
structure (PDBID 3MI9 [44]), with backbone RMSD of 1.8 A˚.
Table 5.9 Intermolecular HBs and hydrophobic contacts between Tat•P-TEFb
model comparing to Tat and P-TEFb in X-ray structure. The residues with star are
not consistent with HBs found in X-ray structure [44]
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Figure 5.10 Molecular representation of Tat•P-TEFb model and interactions. HCs
are shown in the dot lines. Residues are in sticks with oxygen and nitrogen atoms in
red and blue, respectively. (A) Superposition of Tat in complex with P-TEFb X-ray
structure, PDBID 3MI9 [44] (red, orange, grey for Tat, CDK9 and CycT1, respec-
tively) with Tat•PTEFb model (magenta, green, cyan for Tat, CDK9 and CycT1,
respectively). The backbone RMSD for the two complexes is 1.8 A˚. (B) Intermolec-
ular HBs between Tat (magenta) and CDK9 (green) in Tat•P-TEFb model. (C)
Selected intermolecular HBs between Tat (amgenta) and CycT1 (cyan) in Tat•P-
TEFb model.
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Figure 5.11 Molecular representation of HIV-1 Tat in complex with cellular part-
ners [45, 399, 44, 400]. The PDBIDs are shown in the bar with the starting and
ending position of Tat (red) in the different complexes.
6
Conclusions
HIV-1 protein/human protein complexes may be excellent targets for novel strate-
gies against HIV-1 infection. Here I have used bio-computing tools to investigate
viral protein/human protein complexes involved in two crucial steps of the HIV-1
life cycle. My tools include sequence analysis and sequence alignment, homology
modeling, data-driven docking and molecular dynamics (MD) simulations.
The first complex is involved in viral integration. Integration is a crucial step in HIV-
1 life cycle because proviral DNA is the template for productive infection [401, 30].
HIV-1 integrase (IN) catalyzes the integration and hence plays a crucial role
in integration. Recently, our collaborator M. Giacca has discovered that human
prolyl-isomerase-1 (hPin1) is a requisite for efficient HIV-1 integration and in-
fection [31]. hPin1 is composed by two domains: amino-terminal domain (’WW’,
amino acids 1-39) and carboxy-terminal peptidyl prolyl-isomerase domain (’PPIase’,
amino acids 45-163). WW domain binds specifically to pSer1 -Pro motifs in HIV-1
IN and PPIase domain catalyzes the cis-trans isomerization of the pSer-Pro bonds
[32, 33]. Here I predicted the structure of HIV-1 IN and in complexes with the two
domains of hPin1.2 We focused on the interactions between the monomeric form
of the viral enzyme. The model was validated by site-directed mutagenesis experi-
ments. We notice that, in our model, HIV-1 IN-Lys136 and IN-Asp207 are involved
in stabilizing interactions in both hPin1-WW and hPin1-PPIase complexes. There-
fore, we predict that mutation of these residues reduce the HIV-1 IN•hPin1 binding.
The experiments, performed by our collaborator Prof. Mauro Giacca, confirmed
that this is indeed the case.
My modeling allowed us also to suggest that, upon binding to hPin1-PPIase, the
mutual configurations of the protein domains rearrange while the catalytic core of the
HIV-1 IN remains unaffected. On the other hand, when HIV-1 IN binds to hPin1-
WW, it does not undergo a conformational change. In addition, my model provides a
1pSer: phosphorylated Serine
2Some of the calculations in this research were carried out by Dr. Vincenzo Carnevale (Temple
University, US) and by Dr. Vanessa Leone (Max Planck Institute of Biophysics, Germany)
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possible rationale for a variety of mutations involving charged residues on the surface
of the viral protein. 3 They are known to hamper virus replication in vivo without
significantly affecting integrase enzymatic activity (class II mutants) [328, 34, 35, 36,
37]; indeed, according to our model, these residues form key interactions with hPin1.
Thus, mutation of these residues is likely to affect HIV-1 IN•hPin1 interactions and
hence IN stability in vivo. The second complex is involved in the viral transcription.
Transcription produces multiple copies of viral RNA, which encode for viral proteins
and enzymes. Mounting evidence suggests that lysine acetylation may be the major
post-translational modification that regulates transcriptional activatity [402, 403,
404, 45]. Therefore, human p300/(CREB-binding protein)-associated factor (PCAF)
bromodomain association with a lysine-acetylated peptide derived from Tat lead to
Tat-mediated HIV-1 transcriptional activation [45]. I predicted the full length of
HIV-1BRU Tat in complex with PCAF bromodomain.
4
My prediction was here particularly challenging because HIV-1 Tat is an intrinsically
disordered protein (IDP) [405]. Moreover HIV-1 Tat in complex with cellular part-
ners can adopt a wide variety of conformations [45, 399, 44, 400]. The model turns
out to be consistent with experimental data [45, 362, 46]. In addition, the charac-
terization of Tat•PCAF bromodomain binding may help in defining the structural
determinants of other protein interactions involving lysine acetylation [46] (Figure
6.1).
It is our hope that the structural information provided here, which has been made
freely available to the scientific community, might help drug discovery processes
which involve the design of drug-like compounds interfering with the binding of
viral proteins to their cellular partners [406].
3These include: HIV-1 IN-Lys34, -Asp55, -Arg199, -Lys211, -Lys215, and -Lys219
4So far neither X-ray crystallography nor NMR spectroscopy have provided the structure of full
length HIV-1 Tat in complex with the host partners [39, 405]
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Figure 6.1 HIV-1 full length Tat with acetylated lysine 50 (AcK50) in complex
with PCAF bromodomain. The color blocks of HIV-1 Tat and PCAF bromodomain
are in the bars. The AcK50-Tat residue is represented in stick forms.
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